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ABSTRACT 
Recent clinical studies have shown that grapefruit improves insulin resistance, reduces 
weight gain in humans and is associated with unwanted drug interactions. 
However, despite the abundant knowledge on the effects of grapefruit juice (GFJ) on 
intestinal drug transporter proteins [organic cation transporter protein (OATP), P-
glycoprotein (P-gp)] and drug metabolizing enzymes (CYP3A4), the effect of GFJ on 
hepatic metabolism has not previously been critically examined. Potential effects of GFJ 
on other hepatic drug transporter proteins, such as organic cation transporter protein 
(OCTI), could affect the pharmacokinetics and pharmacodynamics of substrates such as 
metformin. The effects of GFJ on glucose tolerance, OCTI expression in the liver and 
metformin-induced lactic acidosis in normal, non-diabetic in rats, are hereby investigated. 
Male Wistar rats, were divided into 3 groups (A, B, C) which were further divided into 4 
sub-groups designated A1-A4, BI-B4 and C1-C4 of 5 animals each, respectively. Su-
bgroups AI-A4 were treated with 0, 1.0,2.0, and 3.0 ml/kg body weight of grapefruit juice 
(GFJ), respectively, while sub-groups BI and B3 were each treated with an oral dose of 
3.0 ml/kg body weight of GFJ, respectively. Sub-groups B2 and B4 were similarly treated 
with an equal volume of distilled water. Sub-groups C3 and C4 were given oral doses of 
3.0 ml/kg body weight of GFJ, while sub-groups C1 and C2 were treated with an equal 
volume of distilled water. On the 14th day of treatment, the rats in sub-groups C2 and C4 
were treated with 1.0 ml oral dose of 250 mg/kg body weight of metformin in distilled 
water. Sub-groups B2, B3 and C2, were further treated with subcutaneous injections of 
pregnenolone-16-alpha-carbonitrile (PCN) [17 mg/kg body weight (15 mg/ml in 
propylene glycol)] on the 10th day of treatment, while sub-groups A4 and C1 were treated 
with subcutaneous injections of 1.0 mg/kg body weight/day of dexamethasone for 3 
consecutive days prior to end-point. 
Glucose tolerance test (GTT) was done on all treatment groups on the 14th day of 
treatment by oral administration, or intraperitoneal injection (i. p), of 3.0 g/kg body 
weight of glucose in distilled water, or in normal saline, respectively. Blood glucose 
concentrations were measured at times 0, 30, 60, and 90 minutes. Area-under-the-curve 
{(AVC), (mmollL X minutes = AVC units)} was calculated from blood glucose-time 
xv 
curves. Glycaemic index was determined by trapezoid rule using the formula: Glycaemic 
Index (GI) = AUC (GFJ/AUC(Glucose)XlOO. 
No deaths, or adverse effects, were observed in the LDso study. Net weight gain due to 
natural growth was 76.0±S.7 g in the control rats, compared to 72.8±4.9 g in the GFJ-
treated 'test' rats. GFJ significantly (p<O.OS) lowered plasma glucose and GI, 
respectively, in a dose-dependent manner. However, there was no significant difference 
in plasma insulin levels among all treatment groups. 
GFJ- (409±2S mg/g of liver tissue) or dexamethasone- and GFJ (439±3S mg/g of liver 
tissue)-treated animals had significantly (p<O.OS) increased hepatic glycogen levels, 
compared to control (288±14 mg/g of liver) rats, respectively. GFJ-treatment 
significantly (p<O.OS) reduced glucokinase activity (Km =144 1-lM), even in the presence 
of dexamethasone (Km = 269 I-lM), compared to control rats (Km = 308 1-lM). However, 
GFJ significantly (p<O.OS) reduced G6Pase activity (Km = 2.29 mM; Vmax = 14.02±0.4S 
I-lmol/min/g liver tissue), compared with the controls (Km = 2.068 mM; V max = 13.4±0.4S 
I-lmollmin/g liver tissue). Similarly, GFJ significantly (p<O.OS) reduced (Km = 2.78 mM; 
V max = 10.72±0.3630 I-lmollg of liver tissue/ min) dexamethasone-induced PEPCK 
activity (Km = 0.738 mM; Vmax = 26.78±0.4ll-lmol/g ofliver tissue/ min). GFJ alone (Km 
= 0.02 mM; Vmax = 96.44±2.47 nmoll min/I-lg of liver tissue), or in combination with 
dexamethasone (Km = 0.0321 mM; Vmax = 84.71±3.949 nmoll min/I-lg of liver tissue), 
significantly (p<0.000 1) increased AMPK activity in the 'test', compared to control (Km 
= 0.146 mM; V max = 7.442±0.411 nmol/ min/I-lg of liver tissue) rats. 
Blood lactic acid levels were significantly higher (p=0.0079) in rats that were treated with 
either metformin alone (S.38 ± 2.S3 mmoIlL), or metformin in combination with GFJ 
(8.31 ±2.5 mmoIlL), than in control (2.54 ± 0.7 mmollL) rats, respectively. Linear 
regression analysis showed significant correlation between liver tissue metformin 
concentrations, and plasma lactic acid levels in both control (p= 0.0122; r2 = 0.9080) and 
GFJ-treated 'test' rats (p= 0.0005; r2=0.9893). 
Densitometry scans expressed as a percentage of the controls showed that GFJ 
(285.6±33.4%) significantly (p<O.OS) up-regulated the expression of OCTI in the liver, 
compared to controls. 
XVI 
Although GFJ improves glucose tolerance, and may be beneficial in diabetic patients 
with metabolic syndrome, caution should be exercised in patients who are on concurrent 
medication with metformin. 
xvii 
CHAPERI 
INTRODUCTION AND LITERATURE REVIEW 
1.1 The Citrus fruit 
Grapefruit (Citrus paradise Macf., family, Rutacaeae), is consumed worldwide not only 
because of its taste and nutritional value, but also because of its accredited medicinal 
properties [1]. Other members of the genus Citrus are oranges, lemons, limes and 
mandarins (tangerines) [2]. Citrus is an ancient crop with records of cultivation dating 
back to 2100BC [3], and is thought to have originated from South East Asia (East India, 
Burma and South West China), [3,4], but is currently distributed worldwide, courtesy of 
ancient explorers and travellers [2]. Commercial grapefruit varieties were mainly 
developed in Florida, but at present, grapefruit is largely produced in USA, Israel, Cuba, 
Argentina and South Africa [5]. 
Classification of the Citrus fruit is still contentious among plant taxonomists, who 
nevertheless, believe that the grapefruit originated in the Caribbean Islands (West Indies) 
in the early 1700s, by hybridization between orange and shaddock [1, 5]. However, 
recent molecular biology techniques using inter-simple sequence repeat (ISSR), 
microsatellite probes, random amplified polymorphic DNA (RAPD), restriction fragment 
length polymorphism (RFLP), and sequence characterised amplified region (SCAR) have 
shown that the grapefruit is most probably a hybrid between pummelo (c. grandis) and 
sweet orange (c. sinensis), followed by introgression back to pummelo [2,6,7]. The 
original grapefruit was white-fleshed and very seedy, but other mutated fruit varieties 
have been selected for either being seedless or increasingly red in colour [2]. Such 
varieties include, Duncan/Walters (seedy white), Marsh (seedless, white), Foster (seedy, 
pink), Thompson (seedless, pink), Redblush (seedless, red), and Ruby, Ray Ruby, Flame 
(seedless, very red) (Figure 1) [2]. These pigmented cultivars have now become more 
popular and are generally preferred to white grapefruit in the market [8]. 
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1.1.2 Medicinal properties of grapefruit 
Traditionally, consumption of grapefruit juice was indicated for such diverse ailments as 
anoreXIa, microbial infections, cancers, rheumatism, insomnia, dysuria and 
cardiovascular disorders [1]. Citrus fruits in general, and grapefruit in particular, are 
considered to be functional foods that promote good health, and have been shown by 
preliminary medical evidence, to be associated with a reduction in the development of 
atherosclerotic plaque, inhibition of breast cancer cell proliferation, and suppression of 
mammary cell tumorigenesis [9, 10, 11]. Although bioactive compounds present in 
Citrus fruits have been studied for many years, the cellular mechanisms involved in their 
biological actions have not been completely understood. Many pharmacological activities 
of citrus fruits appear to be linked to their ability to modify the activity of mammalian 
enzyme systems such as, kinases, phospholipases, ATPase, lipooxyganases and 
phosphodiesterases [12]. The antineoplastic properties of grapefruit or grapefruit juice, 
for example, have partially been attributed to its modulation of the expression and 
activity of phase II hepatic enzymes (glutathione S-transferase, quinine reductase [13]) 
and free radical scavenging antioxidant activity [8]. Studies by Gorinstein et al [14] have 
suggested that diets supplemented with grapefruit improve plasma lipid levels and 
increase plasma antioxidant activity in experimental animals. Similar studies conducted 
on human subjects have shown that red grapefruit significantly lowers serum total 
cholesterol, low density lipoprotein cholesterol and triglycerides in patients with coronary 
artherosclerosis [15]. Feeding grapefruit juice to senescent male rats has also been shown 
to improve antioxidant status and protect the animals against osteoporosis [16]. 
A recent study by Fujioka et al [17] has reported that consumption of whole grapefruit or 
grapefruit juice is associated with significant weight loss and improved insulin resistance 
in patients with metabolic syndrome, compared to placebo. Grapefruit has been part of 
many diets since its incorporation into the 'Hollywood' diet of hard-boiled eggs, green 
vegetables and 'melba' toast in 1930, as an anti-obesity ingredient [18]. These 
observations, therefore, seem to suggest that consumption of grapefruit or grapefruit juice 
may have beneficial effects in patients with type 2 diabetes mellitus and other 
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degenerative diseases, hence, scientifically justifying the age-old tradition of diet 
supplementation with grapefruit. 
1.1.3 Phytochemistry of the grapefruit 
A wide variety of bioactive compounds in grapefruit juice have been isolated and 
characterised. Their relative abundance varies according to the variety, geographical 
location, time of harvesting and the method of processing of the grapefruit [19]. Four 
types of flavonoids (flavonones, flavones, flavonols and anthocynanins) have been 
identified in the Citrus fruits [12]. Flavonoids constitute the most abundant bioactive 
constituents of the grapefruit, besides limonoid aglycones, glucosides, furocoumarins, 
ascorbic acid, folic cid, glucaric acid, carotenoids, pectin and potassium [20, 21, 22, 23] 
(Table 1). These compounds are believed to be responsible for many of the accredited 
medicinal properties of the grapefruit. The flavonoids (naringin and hesperidin) and 
limonoids (limonin) are responsible for the bitter taste commonly associated with 
grapefruit [24]. Flavonoids exist in grapefruit as glycosides with naringin being the most 
abundant but converted to aglycones and sugars by intestinal bacteria upon ingestion [1]. 
Enzymatic hydrolysis of naringin by naringinase yields naringenin (Figure 2), which has 
been shown experimentally to have pharmacological properties such as anticancer, anti-
inflammatory, antithrombotic, vasodilator as well as antiatherosclerotic activities [25]. 
Naringin has been shown to reduce intestinal glucose absorption, and to modulate the 
expression of key hepatic glucose-regulating enzymes, suggesting that it may be 
beneficial in the treatment oftype 2 diabetes [26, 27, 28]. A recent study by Purushotham 
et aI, [29] has, however, shown that it is naringenin, rather than its glucoside naringin, 
that is responsible the suppression of hepatic glucose production, suggesting that the 
observed effects of naringin could be as a result of in vivo hydrolysis by nariginase to its 
active compound, naringenin. 
Laboratory animal model studies have shown that limonin and abacunone, both 
commonly found in grapefruit, reduce the incidence of colonic adenocarcinomas in rats 
[30], while hesperidine reduced proliferation and induced apoptosis in colonocytes [31]. 
Vanamala et al [32] have shown that consumption of grapefruit or limon in suppresses the 
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development of colon cancer in rats through inhibition of the expression and activity of 
inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). 
Glucaric acid is found in grapefruit in high levels [33], and appears to be beneficial in the 
prevention of carcinogenesis. Currently, oral supplementation with calcium D-glucarate 
is used as adjunct therapy against hormone-dependent cancers, such as breast, prostate 
and colon cancers [34]. The protective effects of grapefruit against degenerative diseases 
in general, and cancer in particular is, therefore, not in dispute. 
1.2 Grapefruit juice-drug interaction 
Despite the many health benefits of grapefruit juice as a dietary component, it has, 
surprisingly, come to light that consumption of grapefruit juice is associated with drug 
interactions. Drug-drug interactions have regulatory processes monitored through 
legislation; but food-drug interactions are difficult to regulate or legislate. The accidental 
observation of pharmacokinetic interaction between ethanol and dihydropyridine calcium 
channel antagonist (felodipine) when grapefruit juice was used as a flavour to mask 
ethanol taste in a study by Bailey et at [35] opened the flood gates to many investigations 
that indeed confirmed grapefruit-drug interactions. Grapefruit juice is frequently taken 
with medications at breakfast by many patients, and this discovery, therefore, came as a 
surprise not only to the citrus industry, but also clinicians and patients alike. Many drugs 
have since been investigated for potential interactions with grapefruit juice, and the 
results now confirm that grapefruit juice does indeed increase oral bioavailability of 
many of such therapeutic drugs. Since 1998, grapefruit juice has been known to increase 
the area under the concentration-time curve (AVC), or maximum plasma concentrations, 
of 34 out of 40 drugs that it has been reported to interact with after oral ingestion, thus 
increasing their oral bioavailability [36]. 
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1.2.1 Cardiovascular drugs 
Calcium channel blockers, commonly used to treat hypertension, have been extensively 
studied for possible interactions with grapefruit juice following accidental discovery of 
interaction of grapefruit juice with a dihydropyridine, felodipine. A study by Lundahl et 
al [37] showed that grapefruit juice increased oral bioavailability of felodipine by 112% 
in healthy men without significantly altering intravenous pharmacokinetics, suggesting 
that grapefruit effects were mediated by gut wall metabolism. Grapefruit-felodipine 
interaction has subsequently been shown to increase with dosing frequency and the 
amount of grapefruit ingested, and that a dosing interval of 2-3 days between grapefruit 
ingestion and felodipine intake was required to overcome this interaction [37, 38]. These 
observations, therefore, provided initial clues that grapefruit juice-felodipine interactions 
could not be as a result of direct chemical interaction, but rather, a consequence of some 
physiological response, and that these effects were partially reversible. 
Grapefruit juice increases oral bioavailability albeit to a lesser extent than felodipine, of 
nondihydropyridines, diltiazem and verapamil, when co-administered [40, 41]. The 
maximum plasma concentration increased as the time taken to reach peak plasma 
concentration ofnisoldipine reduced when grapefruit juice was taken concomitantly [42]. 
Other dihydropyridines, such as nimlodipine and nitrendipine, exhibit a lesser but still 
significant interaction with grapefruit juice than felodipine [43]. Amlodipine and 
nifedipine are similarly less affected by grapefruit juice than felodipine [44, 45, 46]. 
These studies, therefore, led to the conclusion that, the extent of interaction of calcium 
channel blockers with grapefruit juice is inversely proportional to the inherent 
bioavailability, such that drugs with high oral bioavailability, like nifedipine and 
amoldipine, are less affected than felodipine, when co-administered with grapefruit juice. 
Pharmacokinetics studies have subsequently shown that calcium channel blockers with 
smaller bioavailability or lower plasma free fraction are likely to exhibit a more potent 
interaction with grapefruit juice and vice versa [47], suggesting that grapefruit juice could 
be affecting intestinal metabolism of these drugs prior to their pre-systemic circulation. 
Unlike calcium blockers, angiotensin converting enzyme (ACE) inhibitors have not 
shown significant interaction with grapefruit juice. However, grapefruit juice has been 
5 
shown to inhibit the bioactivation of angiotensin receptor blocker losartan, to its active 
metabolite, thus reducing its efficacy [48]. 
Thiazide diuretics and aI-adrenergic antagonists, such as doxasozin, terasozin and 
prazosin, have so far shown no interaction with grapefruit juice [49], but antiarrythmic 
prodrug, amiodarone, is less effective when co-administered with grapefruit juice [36]. 
Grapefruit juice completely inhibited conversion of amiodarone to its active metabolite, 
N-desthylamiodarone, resulting in 50% and 84% increases in AUC and maximum plasma 
concentration of amiodarone, respectively; clinically leading to prolongation of QT 
intervals (which is a measure of the time between the start of the Q wave and the end of 
the T wave in the heart's electrical cycle) [50]. 
Among the cholesterol-lowering agents, grapefruit has been demonstrated to Increase 
serum concentration of simvastatin and its active metabolite, simvastatin acid, and that 
this interaction subsides within 3-7 days after ingestion of the last dose of grapefruit juice 
[51, 52, 53]. Similar observations have been made (to a lesser extent though) when other 
HMG-CoA reductase inhibitors, such as lovastatin and atorvastatin, are taken 
concomitantly with grapefruit juice [36], but pravastatin's (not metabolised in the body) 
bioavailability is not affected by grapefruit juice ingestion, indicating that grapefruit juice 
effect on HMG-CoA reductase inhibitors is a consequence of intestinal metabolism of 
such drugs [54]. Other cholesterol-lowering agents like nicotinic acid and common fibric 
acid derivatives, as well as bile acid sequestrants, have not been reported to interact with 
grapefruit juice [49]. 
1.2.2 Antimicrobials 
Grapefruit juice has significant interaction with saquinavir, a protease inhibitor used in 
the treatment of HIV infection. Oral bioavailability of saquinavir increases by a factor of 
two following ingestion of grapefruit juice, without affecting systemic clearance after 
intravenous administration [55]. Like calcium channel blockers, saquinavir has inherent 
low oral bioavailability [56], suggesting that grapefruit inhibits intestinal metabolism of 
saquinavir. However, grapefruit juice does not appear to significantly affect oral 
bioavailability of indinavir and amprenavir [57, 58, 59]. 
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Grapefruit juice significantly increases oral bioavailability of the antimalarial drug, 
artmeter, and anthelmintic agent, praziquantel, respectively; without affecting their 
pharmacokinetics, thus suggesting a role of intestinal metabolism [59, 60, 61 , 62]. On the 
other hand, the pharmacokinetics of quinine, which is known to have a high inherent oral 
bioavailability, is not affected by grapefruit [36, 63], yet again implicating intestinal 
metabolism as the site of action of grapefruit. However, grapefruit has been 
demonstrated to reduce total clearance and increase elimination half-life of quinidine by 
19% [64]. Administration of grapefruit juice increases time-to-peak concentration of 
clarithromycin without affecting other pharmacokinetic parameters [65] , suggesting a 
facilitation of clarithromycin uptake by grapefruit juice. 
1.2.3 Central nervous system drugs 
Benzodiazepines, being the most commonly-used sedatives-hypnotics, have been 
investigated for potential interactions with grapefruit juice. A single glass of regular 
strength grapefruit juice was shown by Ozdemir et al [66] to increase the AVC of 
diazepam by more than 3-fold, while a similar amount of grapefruit juice increased the 
AVC and peak plasma concentration of triazolam and midazolam by 50%, without 
affecting their half-lives [67, 68]. Chronic consumption of grapefruit juice also increases 
the AVC of triazolam by as much as 150% [69]. No pharmacokinetic effects have, 
however, been observed with aprazolam even after repeated ingestions of grapefruit juice 
[70]. A 40% increase in AVC has been reported with anticonvulsant carbamazepine after 
oral ingestion of grapefruit juice [71], without affecting pharmacokinetics of phenytoin 
[72]. Increased bioavailability has also been shown when grapefruit is ingested 
concurrently with buspirone, which has inherent low bioavailability [73], and serotonin 
selective reuptake inhibitor, sertralin, has been reported [74] . Antipsychotics, such as 
clozapine and haloperidol, however, remain unaffected by grapefruit juice consumption 
[75, 76]. 
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Antihistamines and serotonin analogues most affected by grapefruit juice include 
cisapride [77], racemic nitrendipine which also inhibits metabolism of nitrendipine in 
humans [78, 79]. 
1.2.4 Other drugs 
Sildenafil citrate, a phosphodiesterase inhibitor, commonly used for the treatment of 
erectile dysfunction, has been shown to interact with grapefruit juice. Ingestion of 250 ml 
grapefruit juice 1.0 hour before, or concomitantly with grapefruit juice, increases the oral 
bioavailability of sildenafil by 23% [80]. Ingestion of similar amount of grapefruit juice 
also increases oral bioavailability of cisapride, a prokinetic agent, by 50% [81 , 82]. An 
increase in cyclosporine (an immunosuppressant) AUC of more than 60% has been 
observed after grapefruit ingestion [83, 84] . In paediatric transplant patients, grapefruit 
juice altered oral cyclosporine AUC, peak plasma concentration, as well as elimination 
parameters following oral [85], but not intravenous, administration [83]. Similar 
observations have been made in healthy volunteers [86]. Grapefruit juice has recently 
been shown to affect the formation and/or elimination of cyclosporine metabolites Ml 
and M9 [85, 86, 87, 88], suggesting inhibition of intestinal metabolism of cyclosporine 
by grapefruit juice. 
Concurrent administration of grapefruit juice in postmenopausal women has been shown 
to increase oral bioavailability of estradiol [89]. Similarly, Dasgupta et ai, [90] reported 
that grapefruit juice increases plasma concentration of paracetamol by increasing 
elimination half-life in mice, thus suggesting for the first time that there could be hepatic 
involvement in grapefruit juice-drug interactions. 
1.3 Mechanism of grapefruit juice-drug interactions 
Grapefruit juice-drug interactions have been investigated using regular or double strength 
(reconstituted with less water) juice, with a single glass, or repeated ingestions [91] , and 
the results consistently show that ingestion of single glass (250 ml) of grapefruit juice is 
enough to produce maximum effect [79, 92], even though repeated dosing produces 
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higher intensity interactions [69]. These studies, therefore, confirm that grapefruit juice-
drug interaction is not dependent on concomitant administration of both. Lovastatin 
bioavailability is doubled even if taken 12 hours after grapefruit ingestion [93], and 
felodipine-grapefruit juice interaction persists at 30% of its maximum effect 24 hours 
after grapefruit juice ingestion [94]. Studies by Takanga et aI, [95] have reported that 
grapefruit juice impact can last up to 3 days. These observations have led investigators to 
believe that grapefruit juice-drug interactions are mediated by enzyme inhibition, since it 
became apparent that an interval of 24 hours between ingestions of grapefruit juice is 
required to overcome the interaction [53]. This theory was further re-enforced by the 
consistent reports that drugs with inherently low bioavailability are most affected by 
grapefruit juice, suggesting that these drugs undergo extensive intestinal metabolism by 
enzymes that may be inhibited by grapefruit juice or its constituent chemicals. 
1.3.1 Molecular insight 
In the human body, organs concerned with drug disposition, such as the liver, the 
intestines and the kidney, actively express drug metabolising enzymes and transporter 
proteins in response to local or systemic exposure to xenobiotics. The response to 
xenobiotics exposure may be in the form of induction, constitutive or repressed 
expression of these enzymes and proteins [96]. Such responses are mediated and 
regulated by nuclear receptors, such as Pregnane X Receptor (PXR) , Constitutive 
Androstane Receptor (CAR) and many others. 
pXR is a member of the nuclear receptor superfamily of proteins which constitute a large 
group of transcription factors that regulate expression of target genes of endobiotics as 
well as xenobiotics. Ligand binding activates these receptors to induce target gene 
expression by binding to specific response elements within the promoter regions of the 
target genes [97, 98]. These proteins, therefore, mediate signal transduction cascade, 
which leads to the synthesis of drug metabolizing enzymes and transporters of 
endobiotics and xenobiotics. Other members of this superfamily include Retinoid X 
Receptors (RXR) [99], Peroxisome-Ploriferator-Activated Receptors (PPAR) [100], 
Farnesoid X Receptors (FXR) [101], Liver X Receptors (LXR) [102] and Constitutive 
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Androstane Receptors (CAR), [103]. Expression of PXR, also referred to as steroid and 
xenobiotic receptor (SXR) in humans [104], predominantly occurs in the liver and to a 
lesser extent, in the intestines [105], and is activated by many structurally-diverse 
compounds, such as pregnenolone 16a.-carbonitrile (PCN), rifampicin and 
dexamethasone [105, 106]. PXR is known to be promiscuous with regard to ligand 
specificity, and is a powerful regulator of phase I and phase II enzymes of hepatic 
metabolism as well as several cellular transporters [107, 108]. In the liver and intestines, 
PXR regulates the expression of CYP3A and 2B genes [107], and many other proteins 
involved in drug disposition. Molecular studies have shown that, following ligand 
(xenobiotics as well as endobiotics) binding, PXR trans locates to the nucleus by 
facilitated nucleus diffusion, dimerizes with RXRa. and then binds the 5' -regulatory 
regions of target genes including CYP3A family [109], and causes transcription of 
relevant genes (Figure 3). In the absence of an activating ligand, or in the presence of an 
antagonist, corepressors are thought to bind PXR and deacetylate histones, preventing 
transcription of target genes [110]. PXR up-regulation of CYP3A4 in human tissues is 
particularly significant, taking into account the grapefruit juice-drug interactions. The 
potential of grapefruit juice to modulate the activity of this enzyme via PXR can not be 
ruled out. The combined activity of cytochrome P450 enzymes and drug transporters is 
responsible for the drug interactions involving many therapeutic agents. However, factors 
controlling regulation of the expression of drug metabolising enzymes and transporter 
proteins in different tissues in the human body are still not well understood. 
1.3.2 Cytochrome P450 enzymes 
Drug metabolising systems are primarily located in the liver and small intestines, and to a 
lesser extent in other organs such as the lungs and adrenal glands [111]. Oxidative drug 
metabolism occurs mainly to terminate its action and render it less lipophilic for 
enhanced renal clearance. Cytochrome P450 is a large multi-gene family of heme-
containing enzymes located in the endoplasmic reticulum of cells [1], and constitutes 
major drug metabolising enzymes in humans, comprising many isoforms which, to a 
large extent, are drug specific. These enzymes have been named by a code-like 
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nomenclature with Arabic numerals for the families, followed by a letter defining the 
sub-family and the last number for the enzyme within the sub-family (eg, CYP lA2, 
CYP2C9, CYP3A4, etc). About half of the therapeutic drugs used in humans are 
metabolised by CYP 3A4, which appears to be more promiscuous with respect to drug 
specificity [112]. Cytochrome P450 enzymes are inducible by, amongst others, increased 
substrate concentrations, such that exposure to a drug or dietary substances triggers 
increased expression/activity of the relevant isoform. This leads to increased drug 
metabolism, and hence, elimination from the body. It, therefore, follows that inhibition of 
these enzymes conversely leads to accumulation of the substrate drug in plasma, and vice 
versa. 
Cytochrome P450 may be inhibited or induced by many diverse drugs, and xenobiotics, 
such as food components, leading to food-drug interactions [113]. Unlike drug-drug 
interactions, which have been well studied, food-drug interactions have only recently 
been noticed [113, 114]. 
Grapefruit juice-drug interactions are known to be mediated by inhibition of intestinal, 
but not liver, CYP 3A4 [115], since grapefruit juice does not affect the pharmacokinetics 
of the same drugs when administered intravenously [37, 83]. Grapefruit juice inhibition 
of CYP3A4 leads to reduced first-pass metabolism and increased intestinal absorption, 
resulting in elevated maximum plasma concentration. Hence, drugs which are substrates 
of CYP3A4 are the most affected. The half-life and distribution of the substrate drug is 
not affected by grapefruit juice inhibition of CYP3A4 [116]. Grapefruit juice inhibition 
of drug metabolism appears to be partially reversible as the normal CYP3A4 activity is 
restored only after 24 hours post administration of grapefruit juice [94, 117]. The 
duration of the inhibition is dose-dependent, and may persist in reduced magnitude for up 
to 3 days [94, 118]. Currently, laboratory evidence indicates that grapefruit juice 
accelerates the degradation of cytochrome P450 enzymes, and also reduces translation of 
these enzymes from mRNA without affecting transcription of mRNA from cellular DNA 
[1,36,94, 119, 120]. This, therefore, suggests that grapefruit juice inhibition ofCYP 3A4 
is mechanism-based, rather than competitive. It has been noted that grapefruit juice 
reduces the levels of CYP3A4 in the cells by as much as 47% within 4 hours after 
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ingestion of grapefruit juice, with a resulting increase in bioavailability detectable at 
30%,24 hours later [1, 36, 94, 119]. This reduction in CYP3A4 is not accompanied by an 
increase in cellular mRNA content, suggesting that there could be no feedback regulatory 
mechanism on intestinal expression ofCYP3A4 in this context [1]. However, restoration 
of intestinal activity of CYP3A4 has been noted to require de novo synthesis or 
enterocyte replacement [49], which may, therefore, account for the prolonged duration of 
grapefruit juice effects, and also explain the apparent partial reversibility of grapefruit 
juice effects observed by Greenblatt et al [121]. 
Experminentally, it has been demonstrated that grapefruit juice, or its component(s), 
metabolically activate CYP3A4, which in tum gets irreversibly inactivated by covalent 
binding in a mechanism-based interaction [36, 122], suggesting that certain ingredients in 
grapefruit act as suicide substrates of CYP3A4. In vitro experiments using cell-free 
enzyme assay systems and human carcinoma cell (Caco-2 cells) have recently indicated 
that grapefruit juice-CYP3A4 interaction is mechanism-based [119, 123, 124]. Some 
researchers have, however, suggested that some chemicals in grapefruit juice exhibited 
competitive (reversible) inhibition of CYP3A4 in vitro [125, 126]. It is not yet known for 
certain which one of these two different mechanisms precisely contributes to grapefruit 
juice-drug interactions, but available evidence so far favours mechanism-based 
interaction [124, 127]. Clinical studies have, however, shown that grapefruit juice inhibits 
intestinal, but not hepatic, CYP3A4 [37, 68, 83], which may explain the fact that 
grapefruit juice reduces oral biovailability of many drugs without affecting their 
pharmacokinetics. What is puzzling, however, is why would this interaction occur only 
with intestinal and not hepatic CYP3A4? Does the intestine express a different isoform 
of the enzyme from the liver, or is it because the intestine is exposed to high 
concentrations of grapefruit chemical compounds which do not effectively reach systemic 
circulation to influence hepatic metabolism? These questions remain unanswered to date. 
However, there is evidence to suggest that grapefruit juice inhibition of CYP3A4 could 
affect hepatic CYP3A4 upon long-term exposure, since the current studies have only 
looked at acute effects [128]. A study by Lilja et al [69] suggested that grapefruit juice-
triazolam interaction is probably as a result of inhibition of hepatic CYP3A4 after 
prolonged exposure. 
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Recent studies have, however, shown that inhibition of cytochrome P450 enzymes by 
grapefruit juice is not limited to CYP3A4 only [129]. CYP 3A4 and CYP2C9 
(constituting 80% and 15%, respectively) are the predominant intestinal cytochrome 
P450 enzymes, while others such as CYP2D6, 2C 19 and 212 are expressed to a lesser 
extent [130, 131]. Grapefruit extracts have recently been shown to inhibit the activities of 
CYP2D6 and 2C9 in vitro [130]. Grapefruit juice chemical constituents, such as the 
furanocoumarins, have been reported to inhibit other isoforms, such as CYP2CI9, 2EI, 
IAI,IA2 and IBI [120, 132, 133, 134, 135]. 
Evidence from molecular studies indicate that cytochrome P450 gene expression in 
response to xenobiotic activation is mediated by nuclear hormone receptors, such as 
PXR, Constitutive Androsterone Receptor (CAR) and Peroxisome-Ploriferator-Activated 
Receptor (PPARu), which bind to characteristic DNA response elements in the 5'-
regulatory regions of the genes [136] (Figure 3). Dietary chemicals are known to directly 
or indirectly modulate steroid hormone receptors that regulate gene expression of 
cytochrome P450 enzymes, but no studies have been reported on grapefruit juice 
chemical constituents to that effect. 
1.3.3 Drug transporter proteins 
The intestinal barrier, being the gateway to systemic circulation, is endowed with 
gatekeepers that limit the absorption of many xenobiotics which may be derived from 
dietary factors, intestinal microbiota or therapeutic medicines. These proteins work in 
concert with cytochrome P450 enzymes in the enterocytes to limit oral biovailability of 
many drugs [137]. Such proteins include ATP-binding Cassette drug transporters (ABC 
transporters) and Solute Carrier (SLC) transporters [138, 139]. 
Different families of ABC transporters (also referred to as drug efflux pumps) have been 
described in the intestinal tissue, including ABCBA {multidrug resistance protein 
(MORl)}, ABCCI-6 {Multidrug Resistance-associated Protein (MRPI-6)} as well as 
ABCG2, {Breast Cancer Resistance Protein (BCRP)} [138]. These transporters extrude 
drugs, xenobiotics and metabolites from the intestines by active transport in an ATP-
dependent manner, hence, the name ABC. This leads to reduced absorption of drugs or 
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xenobiotics into systemic circulation, thus protecting the body against acute and chronic 
toxicity of toxins [138]. ABCI substrates include anticancer agents, calcium channel 
blockers, antiviral, immune suppressive agents and dietary components [138] (Table 2). 
Consequently, the occurrence of these proteins in the brush-border of intestinal epithelia, 
and their broad substrate specificity, has been associated with multidrug-resistance, 
especially in cancer chemotherapy. 
Different families of SLC drug transporting proteins, such as Organic Anion Transporting 
Polypeptides {OATP (Oatp in rat)}, Organic Cation Transporters {OCT, (Oct in rat)}, 
Organic Anion Transporters (OAT), have similarly been described in intestinal tissues, 
but unlike ABC drug transporters, these proteins improve absorption of many substrate 
drugs and xenobiotics [138, 140]. 
However, drug transporting proteins, are not only expressed in the intestines, but also in 
the liver, kidney, placenta, testis, brain and other tissues concerned with drug disposition 
[141]. SLC family members show wide tissue distribution, but in the liver, they mainly 
mediate hepatic uptake of substrates, and may also support bidirectional transport, 
depending on relative concentrations of their substrates across the sinusoidal membrane 
[142]. Hepatic uptake of organic anions, cations, prostaglandins and other xenobiotics is 
facilitated by dedicated transport proteins in the basolateral (sinusoidal) membrane of 
hepatocytes [142] (Figure 4). These proteins extract drugs, metabolites and other 
xenobiotics into hepatocytes for oxidative enzyme metabolism. Efflux pumps on the 
canalicular domain of hepatocytes, working in concert with these proteins, extrude 
metabolised drugs and other compounds from the cell interior, thus maintaining a 
concentration gradient across the cell [142] (Figure 4). Expression of these proteins is 
subsequently regulated by their substrate xenobiotics/endobiotics, which may lead to 
drug interactions. Many of the hepatic carrier proteins belong to the SLC family, but 
unlike ABC family of proteins, they are mainly found in the basolateral membranes, 
where it has been suggested that they may act both as influx and efflux pumps, depending 
on substrate concentration gradient across cell membrane [142] (Figure 4). An inward 
proton gradient at the brush-border maintained by Na + I'lr exchanger has been proposed 
to be the main facilitator of SLC-mediated transport in the intestines [143]. SLC 
substrates are mainly low molecular weight compounds, which may be metabolised in 
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phase 1 hepatic metabolism by CYP450 enzymes, then followed by phase II 
conjugationlhydroxylation reactions [142]. The products of phase II reaction may exit the 
cell via efflux pumps, such as MRP 113 (into systemic circulation), or P-glycoprotein (P-
gP) and MRP2 located on the canilicular membrane (Figure 4). Alternatively, SLC 
substrates may be taken out of the cell by the same efflux pumps without being 
metabolised (Figure 4). 
Efflux pump substrates are usually relatively high molecular weight compounds, which 
are either secreted via the bile canaliculi, courtesy of canalicular membrane embedded 
efflux pumps, or urine, after extrusion into systemic circulation by MRP 113 or other 
pumps on the basolateral membrane [144] (Figure 4). Therefore, it can be argued that 
substrate specificity for hepatic transporter proteins of drugs and their metabolites 
determines whether a drug will be excreted in urine or in bile. For example, paracetamol 
which is biotransformed in phase II hepatic metabolism to a glucuronic acid conjugate, is 
excreted in urine because glucuronide has a higher affinity for MRP3 (located on 
basolateral membrane) than MRP2 (located on the canilicular membrane) [145]. 
Members of the ABC family are predominantly found on the canalicular membrane of 
hepatocytes where they function as efflux pumps that transfer drugs and their metabolites 
from hepatocyte to bile, uphill against a lOa-WOO-fold concentration gradient [142]. 
MRPs are expressed in many tissues and organs, especially those that protect delicate 
organs like the blood-brain-barrier, placental barrier, liver, lungs, kidney and intestine 
[142]. MDRs equally have a wide tissue distribution, while some, such as MDR3 and 
MDR2, are exclusively expressed in the liver [142]. Expression of drug transporters in 
the liver has been shown to exhibit adaptive response as shown by the observation that 
ligation of bile duct in rats decreases expression of MRP2 in the liver, but increases its 
expression in the kidney, and at the same time upregulates MRP3 expression in the 
kidney [146, 147]. Thus, by down-regulating the expression of hepatic canalicular 
membrane-bound MRP2, and up-regulating the expression of hepatic basolateral 
membrane-bound MRP3 as well as kidney MRP2, the adaptive response in this case 
enhanced drug efflux when the normal exit route (bile duct) was blocked. A recent 
clinical study by Chen HL et al. [148] reported that in children with biliary atresia, bile 
salt export pump (BSEP), MDR3, NTCP, OATP, MRP2 and FXR are all down-regulated 
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at early stages, while at late-stage of the disease, MDRI and MDR3 are up-regulated, 
while PXR is down-regulated in response to cholestasis. These observations suggest that 
the expression of hepatic transport proteins is adjustable to disease states, such that at 
late-stage cholestasis, the overall response is to decrease bile acid uptake, but not 
canalicular export, or biliary pressure. 
1.3.3.1 P-glycoproteins (P-gp) 
P-glycoprotein (also known as P-gp, ABCl or MDRl), a product of the mdrl gene, is the 
most studied member of ABC family of proteins [149, 150]. The 170 kDa protein was 
first discovered in the plasma membrane of mammalian cells that had been selected for 
resistance to drugs [151]. The human P-gp has 4 domains fused into a single polypeptide 
in an H2N-(MD-NBD-MD-NBD)-COOH configuration [149]. Two transmembrane 
domains (TMD) with 6 segments each, form the ligand binding sites, and two cytosolic 
nucleotide binding domains (NBD) bind and hydrolyze ATP to facilitate substrate 
translocation [150] (Figure 5). TMDs are believed to form the pathway through which the 
substrates cross the membrane, while NB domains couple the energy associated with 
ATP binding and hydrolysis to ligand transport [152]. Mutagenesis studies have shown 
that drugs bind TMD4, TMD5 and TMD6 in the N-terminal half, and TMD9, TMD 1 0, 
TMDII and TMD12 in the C-terminal half [153] (Figure 5). The NB domains are highly 
conserved, including the Walker A and B motif, that are found in other A TPases, and the 
characteristic C (signature) motif that is unique to the ABC family of proteins [149]. The 
C motif is thought to be involved in the transduction of ATP hydrolysis energy to the 
conformational changes in the TMD responsible for the translocation of substrates. 
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The precise mechanism by which P-gp mediates transport of ligands across cell 
membranes is still not fully understood, but it is believed that the transport cycle is 
initiated by substrate binding in the transmembrane domain, which increases ATP affinity 
for the protein [150]. After binding and hydrolysis of A TP in one of the NB domains, the 
protein undergoes conformational change, which facilitates the release of the drug/ligand 
into the extracellular space, and then returns to its native state after hydrolysis of a second 
ATP molecule [150]. However, the mechanism that drives the ligand from low to high 
affinity site is still contentious. One model proposes the formation of a closed NB domain 
dimer, which provokes conformational changes that are transmitted to the drug binding 
site followed by two-step sequential hydrolysis of A TP molecules that resets the P-gp 
protein to its native state [158]. The other models propose either one or two hydrolysis 
reactions, which facilitate the efflux of the drug, and the resetting of the protein for 
another cycle [159, 160]. Despite the recent advances in understanding the precise 
mechanism by which P-gp affects ligand efflux, it is still not known precisely how the 
pump mechanically operates, given that its ligands are largely hydrophobic. Classical 
membrane pumps, such as Na ~+ -A TPase, transport polar or charged substrates across 
cell membranes by moving the ligands through a polar channel within the protein 
molecule, thus avoiding contact with the hydrophobic lipid bilayer of the membrane 
[149]. But given the hydrophobic nature of its ligands, it has been suggested that P-gp 
operates in part like "a hydrophobic vacuum cleaner", binding non-polar molecules that 
partition into the membrane and expelling them into the extracellular space [161]. 
However, other schools of thought have it that P-gp operates like a drug "flippase", 
moving substrates from the cytoplasmic membrane leaflet to the extracellular leaflets 
where they can partition into the aqueous phase [162, 163, 164] (Figure 6). 
P-gp substrates include natural products, common therapeutic drugs, steroids, fluorescent 
dyes, linear and cyclic peptides and ionophores [149]. Physiologically, it is known to play 
a central role in drug disposition in many organisms [165]. P-gp is expressed in the apical 
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surface of many epithelial cells such as gastro-intestinal tract, hepatocyte canalicular 
membrane, and endothelial cells that line the brain capillaries, where it forms a major 
component of blood-brain-barrier [149, 166]. In the epithelial cells lining the gut wall, P-
gp is a major factor limiting drug bioavailability [167, 168, 169, 170]. 
P-glycoprotein exhibits broad substrate specificity consistent with its role in transporting 
compounds absorbed into the gut wall back into the lumen [172]. Many therapeutic 
agents are substrates of P-gp (Table 2). It, therefore, follows that any agent that 
modulates the activity of P-gp will equally affect the pharmacokinetics of these drugs. 
This implies that modulators which can block drug efflux activity of P-gp would have an 
impact on the disposition of these drugs. These modulators have been shown to bind to P-
gp at the substrate-binding site, and compete with the transport of substrates in a complex 
fashion [149]. P-gp modulators are known to have similar molecular features to the 
normal transport substrates [175]. Such modulators include calcium channel blocker, 
verapamil, and cyclosporine A, but many others yet to be identified may be found in 
natural products. 
Consumption of grapefruit juice has been reported to modify the activity of enterocyte P-
gpo However, there is no conclusive evidence whether grapefruit juice components inhibit 
or activate P-gp. Evidence supporting grapefruit juice activation of P-gp is scanty, save 
for one study by Sodner et al [176]. The inhibitory effect of P-gp by grapefruit in the 
intestinal wall is supported by the observation that grapefruit effects on bioavailability are 
not apparent when drugs which are substrates P-gp are administered intravenously [55, 
68, 83, 177]. Grapefruit juice has recently been shown in vitro to inhibit P-gp-mediated 
transport of talinolol [178, 179, 180] in Caco-2 cells. Clinical studies have suggested 
that 200 ml of grapefruit juice significantly increases oral bioavailability of 
dextromethorphan, probably by inhibition of P-gp, in human volunteers [181]. A more 
dramatic observation has been made on grapefruit juice interaction with cyclosporin in 
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kidney transplant patients, where grapefruit juice increased oral biovailability of 
cyclosporin, a known P-gp substrate [168] , rather than reducing it. However, Seville 
(sour) orange, a citrus fruit like grapefruit with similar chemical compounds, but which is 
known to reduce enterocyte CYP3A4 concentration, did not affect the pharmacokinetics 
of cyclosporin in the same patients [182]. This observation strongly suggests that 
grapefruit juice increased cyclosporine bioavailability in these patients by P-gp 
inhibition. 
Despite the fact that some drugs are known to be specific substrates of P-gp, grapefruit 
juice does not dramatically affect their oral bioavailability. Digoxin, a well characterised 
substrate of P-gp with negligible metabolism in humans [183, 184], exhibited only a 
modest increase in oral bioavailability when co-administered with grapefruit juice, 
contrary to expectations [185]. It has been argued that, it is the inherent high oral 
bioavailability (70 - 80%) [186] of digoxin, rather than lack of grapefruit juice effect on 
P-gp, that contributed to the apparent reduced absorption [187]. A more confusing 
observation came from studies with fexofenadine, a known substrate of P-gp with an 
absolute oral bioavailability estimated at 33% in humans [187], and eliminated from the 
body unchanged, mainly in the gastrointestinal tract via the biliary tract [186], but 
exhibited a reduced, rather than increased, oral bioavailability when co-administered with 
grapefruit juice [187]. This led to the suggestion that there may be some other drug 
transporter proteins, or metabolic enzymes, which could be involved in transporting or 
metabolising these drugs concurrently, since there is no conclusive evidence at present to 
suggest that grapefruit juice induces or activates P-gp [187]. Surprisingly, these 
observations were similarly made with orange and apple juices, lending further credibility 
to the suspicion that other proteins are involved in the transport offexofenadine [188]. 
Given the fact that both P-gp and CYP3A4 have broad overlapping substrate specificity 
(Table 2), co-localization and functional similarity (reduce bioavailability of drugs), one 
would expect that there exists some kind of co-regulation of the functions of these 
proteins. Both proteins are highly expressed in the liver and the intestines. In the 
intestine, P-gp effluxes drugs absorbed into the enterocyte, while CYP3A4 metabolises 
them, and in the hepatocyte, CYP3A4 and oxidative enzymes metabolise intracellular 
drugs, while P-gp effluxes such drugs and their metabolites into the canallicular space 
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(Figure 4) for biliary excretion. The pertinent question to ask is: is the expression ofP-gp 
and CYP3A4 co-ordinately regulated in both the liver and the intestines, given the 
apparent synergistic nature of their functions in both organs? Several studies seem to 
suggest otherwise [168]. However, the fact that both proteins share common regulatory 
transcription factors (PXR and RXR-a) in both the intestines and the liver, (Figure 3) 
seems to support co-regulation hypothesis taking into account the aforementioned 
adaptive response of the proteins to disease in the liver. 
Despite the paucity of knowledge and conflicting data generated by many researchers, the 
synergistic interplay between P-gp and CYP3A4 has been demonstrated in human 
subjects, using quinidine as a common substrate [190]. In this study, it was shown that 
dose-adjusted plasma quinidine concentrations negatively correlated with intestinal P-gp 
and CYP3A4 protein content, suggesting that oral bioavailability of quinidine was limited 
by both proteins, concurrently. Similar findings have been reported in perfused rat liver, 
where quinidine increased the metabolism of digoxin (metabolised by CYP3A4 in the rat) 
by inhibiting P-gp, which pumps digoxin out of the hepatocyte into canilicular space 
[191]. Even though there is a clear case for co-regulation of P-gp and CYP3A4 in the 
liver and intestines, it has to be taken into account that many other proteins are involved 
in drug disposition in these organs, further complicating the matter and making the search 
for evidence rather elusive. Understanding the mechanism by which grapefruit juice fits 
into this scientific puzzle is indeed a challenging task. 
1.3.3.2 Organic anion transporter protein (OATP) 
Since the isolation of Oatp 1 from the rat brain in 1994, 11 human OA TPs have been 
identified with their genes (SLe2A]), classified by the Human Gene Nomenclature 
Committee, within the gene superfamily (2Al) of the solute carriers [140, 192]. 
Hydropathy analysis has predicted that OATPs contain 12 transmembrane domains 
(TMDs), which include a large extracellular domain between TMs 9 and 10, 
corresponding to extracellular loop 5, and containing many conserved cysteine residues 
that resemble zinc fingers of the DNA binding proteins [193] (Figure 7). Extracellular 
loops 2 and 5 contain N-glycosylation sites [194], while the "OATP superfamily 
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signature" is found at the border between extracellular loops 3 and TMD 6 [140] (Figure 
7). At the boundary of TM domains on cytoplasmic side, conserved amino acid 
sequences are common. 
Functionally, the transport mode of OATPs has been suggested to involve sodium 
independent bile salt and organic ion transport systems, which uses anion exchange as 
well as taurocholate/HC03-exchange mechanisms [195, 196, 197, 198, 199,200]. Details 
of these mechanisms are at present unkown, but it has been suggested that physiologic 
glutathione efflux from hepatocytes creates a driving force that facilitates substrate 
uptake by Oatpl in experimental conditions [201, 202]. 
OA TPs have a broad substrate specificity, but in general common substrates are mainly 
anionic amphipathic molecules with relatively high molecular weights (>450), and 
normally bound to proteins [140]. Common features of the substrates tend to include 
steroid nucleus (e.g bile acids, steroid hormones and their conjugates), and small linear 
and cyclic peptides [140]. It is, therefore, not surprising that OATPs are predominantly 
expressed on the basolateral side of the hepatocytes, since, their substrates, amongst 
others, constitute bile constituents, which are extracted from blood capillaries. In the 
liver, OA TP-B, OA TP-C and OA TP8 are expressed on the sinusoidal (basolateral 
membrane) where they effect uptake and elimination of xenobiotics [140]. On the other 
hand, hydrophilic compounds with low protein binding capacity are excreted in urine, 
and are mainly substrates of OCTs and OA TPs, which are predominantly found on 
basolateral membranes of the hepatocytes [203, 204] (Figure 4). Drugs which are 
substrates of OATPs include opioid receptor antagonists, enkephalin and deltorphin 
[205], enalapril and tempcaprilat [206, 207], and fexofenadine [188], methotrexate [208], 
repaglinide [209] and levothyroxine [210]. OA TPs have also been reported to transport 
digoxin across cell membranes in the rat liver, the brain and the kidney [196, 211, 212, 
213, 214]. In the rat, hepatic uptake of digoxin has been demonstrated to be mediated by 
Oatp2, but inhibited by amiodarone [214]. Dogixin which is known to have a narrow 
therapeutic window [215], is not metabolised in the body [216], and is a substrate of P-
gpo Therefore, it is rational at this point to suggest that P-gp and OA TP co-regulated 
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digoxin' s pharmacokinetics in the body, such that OATP facilitates cellular uptake of 
digoxin while P-gp concurrently enhances its cellular exit. 
HMG-CoA reductase inhibitor, pravastatin, is a substrate of OA TP [217]. Pravastatin 
uptake by hepatocytes was demonstrated to be inhibited by OA TP substrates, such as bile 
acid and bromosulfophthalein, in a competitive manner [218, 119]. Subsequently, Oatp2 
has been confirmed to mediate pravastatin uptake in the rat liver [220]. Potential 
inhibitors of OA TPs may include natural products found in foods, herbs, and other 
sources. The surprise finding that grapefruit juice reduces, rather than increases, 
fexofenadine biovailibility contrary to expectations, has led reasearchers to point 
accusing fingures at OATPs as the "other protein" which antagonises P-gp-mediated 
fexofenadine uptake in the enterocytes. Both P-gp and OATP are located on the apical 
membrane of the enterocytes, where the former acts as an efflux, while the latter as an 
influx facilitator [208] . However, on the hepatocytes membranes, these roles appear to be 
reversed, such that OA TPs located on the sunoisidal membrane facilitate the influx, while 
P-gp located on the canalicular membrane, facilitates efflux of their substrates. This, 
therefore, suggests that, in the intestines, the actions of these proteins oppose each other, 
while in the liver, their combined activity facilitates drug metabolism and elimination. 
Recent evidence has confirmed that indeed human OATPIA2 co-localizes with P-gp in 
immunohitochemical staining [221] solely mediates fexofenadine uptake in enterocytes, 
and is inhibited by grapefruit juice [222]. Glaeser et ai, [222] have showed that co-
administration of grapefruit juice with fexofenadine reduces the AVC of fexofenadine by 
50% when compared to grapefruit juice given 2.0 hours before (38%), without affecting 
the absorption rate, and that this inhibition is abolished when grapefruit juice is 
administered 4 hours before fexofenadine. This shows that grapefruit juice-OATP 
interaction is more complex and difficult to predict than previously thought, and needs to 
be further investigated as there may be other players yet unidentified. 
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1.3.3.3 Organic cation transporter protein (OCTl), the missing link? 
Grapefruit juice interaction with drug metabolising enzymes and transport proteins 
presented here may involve other transporter proteins not yet identified or investiged, 
given the complexity of the interactions so far described. One such drug transporter 
proteins could be organic cation transporter protein 1 (OCTl). 
1.3.3.3.1 Structure and functions of OCT 
The OCTs belong to the family of polyspecific organic cation transporter family of 
proteins designated SLC22, which contains 3 subtypes referred to as OCTI (SLC22AI), 
OCT2 (SLC22A2), OCT3 (SLC22A3), and the cation and camitine transporter OCTNI 
(SLC2A4), etc [224]. OCTI was cloned in 1994, and subsequently 16, additional human 
family members from different species were identified [224, 225]. The members of this 
family have a predictable membrane topology comprising 12 a-helix transmembrane 
domains (TMDs) and an intracellular N- terminus, with a large glycosylated extracellular 
loop between TMDs 1 and 2, a large intracellular loop with phosphorylation sites 
between TMDs 6 and 7, as well as an intracellular C-terminus (Figure 8) [224, 226, 227, 
228, 229]. Tertiary structure model of TMDs and site-directed mutagenesis of amino 
acids have revealed that substrate-binding cleft has conserved amino acids located on the 
4th TMD (tryptophan 218, tyrosine 222 and threonine 226), 10th TMD (alanine 443, 
leucine 447 and glutamine 448), and 11th TMD (aspartate 475), respectively (Figure 8) 
[224, 230, 231]. The leucine 447 residue on the 10th TMD is believed to playa role in 
substrate specificity in the rabbit OCT2 [233]. The glycosylation sites may be involved in 
maintaining protein stability, intracellular routing or protection from extracellular 
proteases [234]. Available evidence from these studies so far suggest that OCTs contain a 
single substrate binding region accessible both from inside and outside the cell 
membrane, but flips direction of substrate transport either inwardly or outwardly during 
the transport cycle [223]. This change in orientation may be accompanied by 
conformational changes within the protein molecule that alters the affinity for substrates 
or inhibitors [223]. 
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The genes coding for OCTI and OCT3 in humans are localized within a cluster on 
chromosome 6.q26-7 [235, 236, 237]. The rat OCTI (rOctI) encodes 556-amino acid 
protein, its homologue (67% identity) rOCT2 encodes 593-amino acid protein, while 
rOCT3 (with 48% homologous identity), encodes 551-amino acid protein with a 
predicted molecular mass of61 kDa [234, 238]. 
Using molecular biology techniques, such as Northern and Western Blots, PCR and 
immunohistochemistry, researchers have shown that OCTI is expressed in epithelial cells 
and some neurons, and that in humans, it is mainly expressed in the liver, whereas in 
rodents, it is strongly expressed in the liver, the kidney and the small intestine, [224, 225, 
240, 241, 242, 243]. These techniques have further shown that in human and rat livers, 
OCTI is located on the sinusoidal membrane of hepatocytes [225, 234] (Figure 4), while 
in the mouse small intestine, it is located on the basolateral membranes of enterocytes 
[246], and in rat kidney, it is found in the basolateral membranes of the epithelial cells in 
the SI and S2 segements of the proximal tubules [240, 241, 244]. OCT2 has a more 
restricted pattern of expression than OCT1, with the kidney being the major organ of 
expression, where it is found in the basolateral membrane of the proximal tubules, like 
OCTI [227, 241, 244]. Unlike OCTI and OCT2, OCT3 has a broad range of expression 
and in humans, the strongest expression occurring in the skeletal muscle, liver, placenta 
and heart, where it is localized largely in the basolateral membrane [243, 245, 246]. 
Functionally, the aCTs (OCTI-3) have similar basic characteristics in various species. 
OCTI and OCT2 share 70% sequence homology (68-69% in humans, rats and mice; and 
71 % for rabbits) [247]. The substrates include a variety of small organic cations with 
different molecular structures, with relative molecular mass of less than 500, and the 
smallest diameter of less than 4 A [248]. Unlike P-gp, aCTs execute bidirectional 
transport of organic cations and weak bases, as well as non-charged compounds [249, 
250,]. At physiological pH, 40% of all drugs are cations, most of which are cleared from 
the body into hepatcocytes by active transport [251]. Models of data obtained from cell-
based assay systems have identified 47 novel inhibitors, and confirmed 15 previously 
known inhibitors of OCTI [251]. Physiologically known substrates of OCT include 
endogenous compounds (dopamine, noradrenaline), xenobiotics, therapeutic drugs 
(metformin, procainamide, atropine, cisplatin, prazocin, amantadine, oxaliplatin, imatinib 
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and verapamil), and model compounds, such as I-methyl-4-phenylpyridinium (MPP), 
[225]. However, some cations {such as tetrapethylammonium (TEA), decaynium 22 and 
disprocynium}, non-charged compounds (corticosterone, deoxycorticosterone and ~­
estradiol), and anions (probencid and a-ketoglutarate) are not substrates, but do inhibit 
OCTs [225]. However, there are differences in substrate/inhibitor specificity of the OCTs 
among animal species, despite the overlap in substrate affinities, such that a substrate of 
one may be an inhibitor of the other, and viee versa [225]. It has been shown for the rat 
and human OCT transporters, that organic cations are transported in an electrogenic 
manner, suggesting that OCTs operate independently of Na+ and membrane proton 
gradients [227,238,249,250,253]. 
Despite close structural and functional similarities, OCTs show remarkable differences in 
substrate affinity, which can be used to distinguish between them. OCT! has higher 
affinity for verapamil, prazosin, atropine, phencyclidine, desipramine, 
phenoxybenzamine, and quinine, than OCT2, which has higher affinity for cisplatin, 
amphetimine, methylenedioxymetamphetamine, amantadine, cimetidine, and 
diphenhydramine, than OCT! in decreasing order of intensity, respectively [225]. 
Substrate affinities and tissue distribution of OCTs suggest a physiological role in the 
distribution of cationic drugs in the liver, kidney, heart and brain, and biliary and renal 
excretion of their substrates [254]. Studies with genetic knockout mice have shown that 
Octl knockout mice {Octl-, (Sle22a] gene knockout)}, Oct2- , (Sle22a2 gene knock out) 
and Oct3-, (Sle22a3 gene knockout) are phenotypically normal, but Octl- knockout mice 
showed dramatically reduced hepatic uptake of met form in and TEA [254, 255, 256, 257, 
258]. It has further been shown that a combined double knockout in Oct 112, led to 
reduced renal excretion and increased plasma level of TEA, which means that a 
combined deficiency of Oct! and Oct2 better reflects the effects of Oct2 deficiency in 
renal function, since Oct! is also expressed in the kidney [254, 256]. Similarly, Oct3-
deficient mice showed reduced uptake of MPP in their hearts and foetuses, compared to 
the wild type [254, 258]. These observations, therefore, emphasize the role of OCTs in 
hepatic and renal uptake, distribution and elimination of drugs and other substrates. 
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1.3.3.3.2 Regulation of OCTs 
Regulation of OCTs involves many factors acting at transcription and post-transcription 
level. Transcriptional control has recently been reported to involve two adjacent putative 
DNA-response elements (DR-2) for hepatocyte nuclear factor-4a (HNF- a) [259]. 
mRNA expression of OCTI was increased by overexpression of HNF-a, and targeted 
disruption of HNF-a dramatically decreased OCTI mRNA in the liver, kidney and 
duodenum [260, 261]. A peroxisome ploriferator agonist receptor (PPAR) response 
element has been identified in the promoter of mouse Oct!, and it has been shown to be 
transactivated by PPAR-y agonists, such as clofibrate and ciglitazone [262]. Further to 
that, it has been shown that the mRNA of rat Octl and Oct2 was increased by treatment 
with pregnenolone-16a-carbonitrile (PCN) which is a known ligand of PXR (Figures 3 
and 9) in the primary cultured cells, rat liver and kidney; and also that biliary expression 
and tissue to plasma ratio of metformin, MPP and TEA (which are known substrates of 
OCTl) increased following subcutaneous administration of PCN [263]. However, 
exposure to dexamethasone, a ligand of glucocorticoid receptor (OR), simultaneously 
decreased rOctl mRNA level and MPP uptake, respectively, which was reversed by 
exposure to a glucocorticoid receptor ligand antagonist, RU486 [264], suggesting that 
dexamethasone down-regulates the expression of rOctl. It is thought that OR-mediated 
down-regulation of rOctl expression may be as a result of decreased PXR expression (> 
I 0 ~ dexamethasone suppresses PXR expression) or by direct OR effects on rOctI 
expression [264]. 
Post-transcriptional regulation of OCT has been proposed to be controlled by its 
phosphorylation status, implying that inhibitors of protein kinase A (PKA), Serc-Iike p56, 
and calmodulin, can modulate the activity of OCTs [265, 266, 267, 268]. OCTI and 
OCT2 seem to share common regulatory mechanisms involving PKA and calmodulin, 
but not PKC which down-regulates OCT2, but not OCTl. It is rational to speculate that 
these regulatory mechanisms involve phosphorylation sites located within the loop, 
forming intracellular domain between TMD 6 and 7, and strategically located within the 
substrate binding pocket (Figure 8). Thus, it would appear that PKA phosphorylation of 
this site deactivates it, and vice versa, while calmodulin stimulates it (Figure 9). 
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However, these observations are made following in vitro studies, and the data obtained 
are still controversial, considering an earlier observation by Mehrens et aI, [269] that 
rOcti is stimulated by PKC, PKA and endogenous tyrosine kinase activation, and that 
PKC phosphorylates rOctI and leads to a conformational change at the substrate binding 
site. Some of these post-transcriptional regulatory pathways could be influenced by many 
ligands, some of which may be components of natural products. 
In spite of the strategic role that OCTI plays in drug disposition in the intestines, the liver 
and the kidney, not much is known about drug-interactions mediated by OCT1. 
Grapefruit juice effects on drugs disposition in the intestines have been investigated in 
detail, but no studies have been done todate, to explore the possibility of such interactions 
taking place in the liver, and to interrogate the involvement of OCTI in this regard, given 
the strategic role it plays in drug disposition in the liver. 
1.3.4 Identifying the culprits in grapefruit juice 
Grapefruit juice is known to contain hundreds of chemical ingredients, some of which 
have been identified as having biological/medicinal properties (Table 1) [271]. Even 
though many studies have been conducted on pharmacological actions of grapefruit juice 
ingredients, definite conclusions on the actual chemical constituents have not been made. 
Indeed, only a handful of such actions have been attributed to specific chemical 
constituents of the grapefruit juice. 
1.3.4.1 Candidate ingredients for CYP3A4 inhibition 
Flavonoids and furanocoumarins commonly found in grapefruit juice and Seville (sour) 
orange, but not in orange juice, have been proposed as the main inhibitors of CYP3A4 
[36, 19]. 
Although naringin is the predominant chemical ingredient in grapefruit juice, recent 
clinical studies have shown that neither naringin, nor its aglycone, naringenin, is 
responsible for the intestinal inhibition of CYP3A4 by grapefruit juice (Figure I) [127, 
272]. In vitro studies have suggested that naringenin does not inhibit CYP3A4 by 
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mechanism-based inhibition, but by competitive antagonism, which is insignificant 
clinically [273]. Co-administration of naringin with felodipine and its primary oxidative 
metabolite, dihydrofelodipine, in vivo produced minimal effects on drug bioavailability, 
suggesting that naringin is not a major inhibitor of CYP3A4 [272]. 
However, furanocoumarins have been shown to inhibit CYP3A4 by mechanism-based 
inhibition, albeit in in vitro, since clinical studies can not be done because 
furanocoumarins have not been approved for human use [36, 274]. Although bergamottin 
is the major furanocoumarin in fresh grapefruit juice [275, 276], available evidence 
suggests that 6',7' -dihydroxybergamottin, and paradisin A, are the major CYP3A4 
inhibitors ofCYP3A4 in vivo [217,278,279]. 
Other furanocoumarins that have been reported to inhibit CYP3A4 include bergapten, 
also found in grapefruit juices, and shown to inhibit CYP3A4 in vitro by mechanism-
based inhibition, but with a lesser potency than 6',7' -dihydroxybergamottin [280]. 
However, bergapten is likely to be a minor ingredient of grapefruit JUice. 
Epoxybergamottin, also present in grapefruit juice in minor quantities, has been reported 
to inhibit CYP3A4 in vitro by mechanism-based inhibition [127, 274]. However, it is 
chemically unstable, and may be rapidly converted to 6',7' -dihydroxybergamottin (in the 
gastrointestinal tract), which may be responsible for the observed inhibitory effects [36]. 
The list of furanocoumarins capable of CYP3A4 inhibiting is still growing, with the 
recent isolation of bergatol and geranylcoumarin from grapefruit, both of which appear to 
be potent inhibitors of CYP3A4 in vitro [281]. Furanocourmarin dimers, GF-I-l and GF-
1-4, occurring in minute quantities in grapefruit juice, have been isolated and shown to be 
potent inhibitors ofCYP3A4 in vitro [282, 283,284]. 
Despite spirited attempts to attribute CYP3A4 inhibition to certain ingredients of 
grapefruit juice, it may be the combined effect of furanocourmarins that produces these 
inhibitory effects. 
1.3.4.2 Grapefruit ingredients that interact with P-gp 
Unlike CYP3A4, P-gp interaction with grapefruit juice has not been finger-pointed to 
individual chemical ingredients in grapefruit juice. There is inconclusive evidence on the 
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effects of flavonoids, (naringin and naringenin), despite suggestions that they do inhibit 
P-gp [36], and furanocoumarins (6' ,T-dihydroxybergamottin), which are found in both 
grapefruit juice and Seville orange, and exert inhibitory effects on P-gp in vitro, only in 
grapefruit juice [36, 274] . Other furanocoumarins, such as psoralens (dermatological 
photosensitizing agents) in citrus fruits have been shown to inhibit P-gp, thus enhancing 
bioavailability of saquinavir [55]. 
1.4 Clinical considerations 
Positive aspects of grapefruit-induced drug interactions are related to the potential 
reduction in costs incurred on reduced treatment regimens of different ailments. 
Grapefruit juice contains a number of health-promoting compounds, which may be 
exploited for therapeutic use. Traditionally, grapefruit-drug interactions have been 
viewed in terms of enhancement of unwanted adverse effects. But recently attempts have 
been made to limit such effects by either modifying the chemistry of the chemical 
constituents of grapefruit juice, or eliminating them altogether. Various laboratories have 
synthesized furanocoumarin dimers, which are believed to be as potent as the natural 
forms but selective in their inhibition of CYP3A4 [285, 286]. It is believed that such 
dimers may be therapeutically exploited to customize grapefruit juice-drug interactions to 
specific patients' needs. A furanocoumarin-free grapefruit juice created by using food 
grade solvents and absorption resins, failed to inhibit CYP3A4 activity, and did not 
increase felodipine ' s bioavailability in healthy human volunteers, thus confirming that 
fur.anocoumarins are the actual ingredients in grapefruit juice that enhance felodipine 
bioavailability [287]. A recent study by Mying et al. [288] has suggested that autoclaved 
edible fungi (Morchella esculenta, Monascus pupureus, Pleuratus sapidus and Agarisu 
hisporus) bind bergamottin and 6 ',T-dihydroxybergamottin, and can, therefore, be used 
to remove furancoumarins from grapefruit juice, without affecting its food quality. 
Previous studies have suggested that heat treatment or UV radiation inactivates 
bergamotting and 6' ,T-dihydroxybergamottin in grapefruit juice, and therefore, 
eliminates pharmacokinetic interaction of grapefruit juice with drugs [289, 290]. Clinical 
benefits of such interventions are yet to be seen. 
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doses, may increase the risk of rhabdomyolysis [52, 54, 294]. With the current trend 
towards a more aggressive lipid lowering therapy with the statins, the risk of 
rhabdomylosis is even greater in patients taking grapefruit juice concomitantly [295]. 
The danger of grapefruit juice-induced drug reaction is particularly grave in drugs with 
narrow therapeutic index, such as terfenadine and cyclosporine. Ingestion of grapefruit 
juice has been reported to increase oral bioavailability ofterfenadine, and prolong the QT 
interval in the electrocardiogram, and precipitate ventricular arrhythmia of Torsade-des-
pointes [296]. A case report has been made of a 29-year-old man who had been taking 
terfenadine twice daily for more than a year, but collapsed and died on the day he took 
two glasses of grapefruit juice [297, 298]. His post-mortem revealed terfenadine 
concentration of 35 ng/ml, which was, therefore, suggested to be the cause of death. 
Fortunately, terfenadine has been withdrawn from the market globally, due to cardiac 
arrhythmias caused by its interaction with other drugs, when taken concurrently [1]. 
Grapefruit juice was noted to increase plasma concentration of cyclosporine in renal 
transplant patients and normal adult volunteers. Such interactions are potentially fatal, 
considering known adverse effects of cyclosporine [299, 300, 301]. However, serious 
calcineurin toxicity has not been reported on these patients, prompting researchers and 
clinicians to believe that regular and moderate grapefruit consumption may allow 
maintenance of cYclosporine plasma levels within a therapeutic range, at a reduced 
dosage [302,303]. 
Geriatric patients and those with liver cirrhosis are particularly at risk. Liver cirrhosis 
patients are more dependent on intestinal CYP3A4 for drug metabolism than those with 
normal liver function [1]. The elderly are particularly vulnerable to grapefruit juice-
induced drug interactions, since they are often on multiple medications, and they 
experience diminished drug disposition capacity [39, 112,304]. 
Another crucial factor to consider in grapefruit juice-drug interaction is genetic 
polymorphism of the CYP3A4 enzyme. It would be expected that patients who express 
intestinal CYP3A4 would extensively metabolise substrate drugs, and hence, experience 
a greater impact of grapefruit juice-drug interactions, and vice versa. However, no large 
scale genotyping data is available to make conclusive evidence in this regard. 
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1.4.1.2 P-gp 
P-gp is the main culprit in multidrug resistance in cancer chemotherapy. Neoplastic cells 
resistant to treatment are known to express P-gp which is responsible for the efflux of a 
large number of drugs [179, 305]. Pharmacological agents which are inhibitors of P-gp 
are linked to adverse effects when taking drugs which are also P-gp substrates (Table 2). 
Calcium channel blockers, such as nifedipine, tlunarizine, verapamil, etc, are known to 
inhibit P-gp activity, causing increased cellular concentration of anthracyclines used in 
cancer chemotherapy such as doxorubicin, daunorubicin, and idiarubicin in 
cardiomyocytes, hence potentiating their cardiotoxicities [306]. Quinidine, verapamil and 
itraconazole are known to increase digoxin blood concentrations and change the 
pharmacodynamics of digoxin in the body by competitive inhibition of P-gp transporting 
functions [307]. The full extent of pharmacodynamic interactions of grapefruit juice 
interactions with P-gp substrates is not fully understood and known. 
1.4.1.3 OATPs 
The clinical impact of OA TP modulation on pharmacodynamics has not been fully 
established, but it has been reported that single nucleotide polymorphism of the OA TP 
gene affects pharmacokinetics of pravastatin [308]. It may, therefore, be speculated that 
OATPs modulators have the potential to enhance or impair cholesterol-lowering effects 
of pravastatin, since patients who express high OATPs in their hepatocytes would 
experience increased hepatic uptake of pravastatin, and vice versa. Considering drug 
interactions, this may, therefore, have serious implications on the pharmacodynamics of 
therapeutic agents, which are OA TP substrates. Such potential dangers have been 
demonstrated by the realisation that rifamycin SV and rifampicin used in the treatment of 
tuberculosis cause hyperbilirubinaemia and reduce elimination of bromosulfophthalein in 
the liver, due to OATP inhibition [140]. In vitro studies have since confirmed that 
rifamycin is a potent inhibitor of rat Oatpl and Oatp2, as well as human OATPs, while 
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its structural analogue, rifampacin, mainly inhibits rat Oatp2 and human OATP8 [309, 
310]. This, therefore, strongly suggests that OA TPs play an important role in the 
enterohepatic circulation of drugs and endobiotics, such that their inhibition would cause 
an increase in plasma concentrations of these substrates, which potentially could lead to 
adverse drug reactions or treatment failure. 
1.4.1.4 OCTt 
Considering the central role that OCTI plays in hepatic uptake and disposition of many 
therapeutic agents, it would be expected that OCTI modulators influence 
pharmacodynamic effects of such drugs. It has been shown that activation of human 
OCTI (hOCT1) by HNF-4a is inhibited by bile acid (chenodeoxycholic acid), via 
component small heterodimer partner (SHP) of the bile acid-inducible transcription 
repressor [260]. HNF-4a is an activator of OCTI expression in the hepatocytes (Figure 
9). Hepatic expression of OCTI is decreased during cholestasis [267]. OCTI expression 
decreases in the liver, but not kidney, after bile duct ligation in the rat, with concomitant 
decreased hepatic accumulation of intravenously injected TEA [267]. This suggests that 
during cholestasis, hepatic bile acid influx pumps are switched off. It has also been 
reported that nephrotoxicity induced by platinum-based antineoplastic agents, such as 
cisplastin and oxaliplatin, is affected by the activity of OCTs, which determines the 
concentration of these drugs in the kidney [311]. 
That PP AR-a and -y response element occurs in the promoter region of mouse Octl 
[312], suggests that PPAR agonists can regulate the expression of OCTI in hepatocytes, 
and currently, they are used in the treatment of diabetes mellitus [312]. 
Interaction of drugs with hepatic transporters may lead to treatment failures or adverse 
reactions when substrate drugs are co-administered, as recently demonstrated in a study 
by Backmakov et al [313], which showed that OCTI-mediated uptake of metformin (l , 1, 
dimethylbiguanide) is inhibited by repaglinide and rosiglitazone in vitro. Studies with 
Octl gene knock-out mice previously showed that accumulation of metformin in the liver 
is reduced, compared to the wild-type [314], confirming that rOctl is the major 
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transporter of metformin into hepatocytes. However, the same study showed that kidney 
metformin levels are comparable in both Octl knock-out mice and wild type, further 
supporting the hypothesis that Octl is the major determinant of metformin disposition, 
both in the liver and in the kidney. 
Recently, Shu et aI, [315] showed that OCTI polymorphisms affect metformin actions 
mediated by adenosine monophosphate-activated protein kinase (AMPK) such as 
phosphorylation and gluconeogenesis, such that glucose-lowering effects are completely 
abolished in Oetl-deficient mice. The study also showed that the effect of metformin on 
glucose tolerance tests were significantly lower in human subjects carrying reduced 
function polymorphisms of OCTI. A similar study further showed that individuals 
carrying reduced function OCTI allele had increased metformin bioavailability [316]. 
These reports, therefore, confirm that OCTI is important for therapeutic actions of 
metformin, and that genetic variations in OCTI gene may contribute to the variations in 
therapeutic response to metformin. It is, therefore, likely that any grapefruit juice effect 
on hepatic OCTI would most probably affect metformin pharmacodynamics. 
Excessive accumulation of metformin and other biguanides in hepatocytes has been 
associated with lactic acidosis commonly seen in diabetic patients taking these 
medications, and OCTI has been implicated [317]. Wang et aI, [317] have showed that 
blood lactate levels increased significantly in wild-type mice, compared to Oetl knock-
out mice, and also in isolated rat hepatocytes with concomitant reduction in oxygen 
consumption in response to metformin and other biguanides. Metformin has been shown 
in in vitro studies, to reduce oxygen consumption and glucose production in isolated rat 
hepatocytes in a dose-depend manner, by inhibition of mitochondrial respiratory complex 
1 [318, 319]. It would be expected that this inhibition causes oxidative stress, which may 
lead to conversion of pyruvate to lactate in the cytosol, and hence, increased lactate 
levels. 
Lactic acidosis is a life-threatening condition characterized by low arterial pH «7.35), 
and elevated lactate levels (5.0 mEq/L in humans), and electrolyte disturbances with an 
increased anion gap [317, 320]. It has been shown that among the therapeutically-used 
biguanides, the affinity of OCT 1 decreases in the order of phenformin>buformin> 
metformin, which is also reflected in their ability to cause lactic acidosis [317]. The 
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incidence of lactic acidosis has been reported by epidemiological surveys to be 
significantly less in diabetic patients taking metformin, than in those taking phenformin 
[320], and indeed, phenformin was subsequently withdrawn from the market when 50% 
of the patients who were taking it died due to lactic acidosis [322]. Metformin is poorly 
metabolised, does not accumulate in the liver, and is eliminated unchanged in urine [321, 
323, 324]. However, there is a growing body of evidence that metformin increases 
glucose utilisation in the small intestine through anaerobic metabolism, and that this leads 
to production of lactic acid, which can be found in hepatic portal vein [325, 326, 327]. A 
recent report by Bailey et aI, [327] has shown that metformin accumulates and enhances 
glucose utilisation in human intestinal mucosa, which leads to significant production of 
lactic acid. However, lactate produced from the intestines is likely to be rapidly removed 
by hepatic metabolism in the liver. 
At cellular level, metformin activates AMPK by phosphorylation, which suppresses 
glucagon-stimulated glucose production, and causes increased glucose uptake by 
hepatocytes and skeletal muscles [328, 329]. The AMPK has previously been referred to 
as "a master sensor, integrator and regulator" of cell and body energy homeostasis [328, 
329]. Activation of AMPK, a well known serine/threonine kinase, is regulated by 
AMP/ATP ratio, and upstream kinases, and affects many pathways that increase cellular 
A TP content [330] in response to such physiological stimuli as exercise, muscle 
contraction and hormones (adiponectin and leptin), as well as physiological stresses, such 
as glucose deprivation, hypoxia, oxidative stress and osmotic schock [331, 332]. Once 
activated, AMPK inhibits gluconeogensis and lipogenesis, while promoting both fatty 
acid oxidation and lipolysis [332]. The precise mechanism by which metformin up 
regulates AMPK expression is not known todate, but it has been shown that metformin 
inhibits the expression of two key hepatic gluconeogenic enzymes, namely 
phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase), 
through AMPK-meditated transcriptional regulation [334, 335]. A recent study by Kim et 
aI, [333] has suggested that metformin inhibition of gluconeogensis (through down-
regulation of PEPCK and G6Pase expression) is mediated by AMPK-dependent 
regulation of small heterodimer partner (SHP), a typical orphan nuclear receptor (which 
lacks DNA-binding domain) that represses the transcriptional activity of a number of 
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nuclear receptors, HNF-4a inclusive [336, 337]. HNF-4a is one of the nuclear factors that 
regulate PEPCK and or G6Pase expression [333]. It is, however, intriguing that HNF-4a 
activation of hOCTI expression is inhibited by chenodeoxycholic acid via SHP [260]. 
This would, therefore, suggest that hepatic uptake of met form in via OCTI is regulated by 
SH. Taking into account the fact that metformin is neither metabolised nor stored in the 
liver, OCTI expression and subsequent metformin uptake and physiological effects in 
hepatocytes may be co-regulated to some extent, could SHP be the focal point? A recent 
study by Kodama et al [338] reported that treatment with PCN, a PXR activator, 
repressed cAMP-dependent induction of G6Pase gene in primary hepatocytes in wild-
type mice, which, therefore, suggests that PXR-mediated up-regulation of OCTI 
expression could parallel suppression of gluconeogenesis in hepatocytes. This implies 
that any xenobiotic ligand that affects OCTI expression via PXR could have an influence 
on regulation of blood sugar. Does grapefruit juice have a role to play in this? No studies 
reported in the current biomedical literature have been done to determine the effects of 
grapefruit juice consumption on hepatic expression of aCTIon metformin 
pharmacodynamics. 
1.4.2 Grapefruit juice effects on metabolic syndrome 
Metabolic syndrome, commonly characterised by abdominal obesity, hyper-
triglyceridemia, low high density lipoprotein, high blood pressure and elevated fasting 
blood sugar, as defined by Adult Treatment Panel III (A TPIII) [339], is a growing public 
health problem [340]. Measures taken to manage metabolic syndrome have previously 
included weight reduction, either through exercise, diet or both. 
Grapefruit juice has traditionally been incorporated into many diets, including the famous 
"Hollywood diet" of hard-boiled eggs, green vegetables, and melba toast [18]. Despite 
the fact that good health promoting benefits associated with grapefruit juice consumption 
have been known for many years, not many studies have been carried out to confirm this. 
The study by Fujioka et aI, [17] was the first and only one todate that has been published 
to confirm that consumption of grapefruit is associated with weight loss and improved 
insulin resistance in non-diabetic patients, with or without metabolic syndrome. In this 
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study, it was suggested that grapefruit could be improving insulin resistance by some as 
yet unknown mechanisms, possibly involving liver enzymes that regulate glucose 
homeostasis. 
Metformin is one the most commonly-used oral antihyperglycaemic agents for the 
management of type 2 diabetes. A United Kingdom Prospective Diabetes Study 
(UKPDS) published in 1998 showed that patients treated with metformin have a 
reduction of 36% in all-cause mortality, 42% reduction in diabetes-related mortality, and 
32% reduction in diabetes-related end-points [341]. Unlike insulin and sulphonylureas, 
metformin administration leads to weight loss in patients with type 2 diabetes mellitus, 
and does not cause hypoglycaemia [342]. Meformin has a much shorter half-life (1.5-5 
h), and is less lipophilic (compared to other biguanides); it is not metabolised by liver 
enzymes, and is eliminated (90%) unchanged by glomerulus's filtration and tubular 
secretion [323, 324, 343]. Metformin is absorbed primarily in the upper part of the 
intestine, and has negligible plasma binding capacity [3446, 345]. 
Therapeutic effects of metformin in diabetic patients, therefore, include decreased fasting 
and post-prandial glucose, decreased glycosylated haemoglobin (HBAJc), weight loss, 
decreased low-density lipoprotein (LDL), and increased high-density lipoprotein (HDL) 
[344]. 
Like other biguanides, metformin-associated lactic acidosis is common in patients with 
renal dysfunction, congestive heart failure, and other conditions that cause tissue hypoxia 
(such as hepatic disease, sepsis, chronic pulmonary disease), which lead to metabolic 
acidosis, and in whom metformin is contraindicated [317, 346, 347, 348]. These co-
morbidities mask the true incidence of metformin-induced lactic acidosis in population 
studies, but a mortality rate of 50% has been reported in patients with lactic acidosis 
taking metformin [349]. Despite claims that metformin-associated lactic acidosis does 
not occur in patients without these co-morbidities, a recent study by Bruijstens et al 
[343], reported the occurrence of lactic acidosis in patients treated with metformin in the 
absence of renal impairment. This suggests that lactic acidosis may occur with or without 
these co-morbidities in patients on metformin therapy. 
The metformin-like effects of grapefruit juice in human subjects, such as weight 
reduction, improved glycaemic index and insulin resistance as reported by Fujioka et al 
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[17], are indeed, intriguing. The as yet unanswered questions in this regard are: does 
grapefruit juice lower blood glucose like metformin? What are the potential implications 
of concurrent consumption of grapefruit juice with metformin - which, unlike other 
medications, is not a substrate of drug metabolising enzymes? If grapefruit juice has 
metformin-like effects on glucose homeostasis, does its consumption affect metformin 
pharmacodynamics? If that is the case, are such effects mediated by modulation of 
hepatic expression of OCTI and other cellular proteins critical to glucose homeostasis? 
Does dexamethasone, a known down-regulator of OCTI expression in hepatocytes 
antagonise these effects? GFJ effects on glucose homeostasis and OCTI expression could 
impact negatively on the therapeutic benefits of metformin in the treatment and 
management of type 2 diabetes. The present study is therefore, aimed at determining the 
potential effects of grapefruit juice on glucose tolerance and hepatic expression of OCTI 
in normal, non-diabetic rats in vivo, using metformin as a reference drug. 
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1.5 Aims and Objectives 
The objectives of this study were to: 
(i) determine the effects of chronic ingestion of grapefruit juice on glucose 
tolerance in normal, non-diabetic rats in vivo, using metformin as the 
'reference drug'; 
(ii) determine the effect of grapefruit juice on the activity of key enzymes 
(glucokinase, glucose6-phosphatase, phosphoenolpyruvate carboxylase and 
adenosine monophosphate-activated protein kinase) regulating hepatic glucose 
homeostasis; 
(ii) determine the effects of grapefruit juice on the expression of hepatic OCTl, 
using PCN and dexamethasone as positive and negative controls, respectively 
in normal non-diabetic rats in vivo; and 
(iii) establish if grapefruit juice-mediated modulation of hepatic expression of 
OCTl affects metformin pharmacodynamics with respect to glucose 




MATERIALS, STUDY DESIGN AND PROCEDURE 
2.1 CHEMICALS REAGENTS AND ACCESSORIES 
Unless otherwise stated, all chemicals and reagents used were purchased from Sigma-
Aldrich™ (SA). 
Animal treatment: glucose, phosphate buffer, normal saline, dexamethasone, 
metformin, portable glucometer and glucose test strips (Ascensia Elite™, Bayer Schering 
Pharma, Germany) were purchased from a local pharmacy. Halothane and other 
accessories were provided by Biomedical Resource Unit (BRU) of the University of 
KwaZulu-Natal, Durban, South Africa. Vacutainer tubes, insulin kit ((DRG Diagnostics, 
Marburg, Germany) 
Immunoblot assays: Tris HCl, SDS, B-mercaptoethanol, Bromophenol blue, Bis-acryl 
amide, ammonium persulphate, TEMED, Trizma base, glycine, methanol, Tween 20, 
KCl, NaCI, rabbit 'anti-rat rOctI antibody, HRP-conjugated goat anti-rabbit antibody 
(BioRad, Hercules, CA, USA), rat anti:-rabbit Na/K-ATPase antibody (Alpha 
Diagnostics, Texas, USA), PVDF membrane filter (Millipore Corp, Bedford, MA), 
Teflon glass homogeniser (Thomas Scientific, Phila~elphia, PA), protease inhibitor 
(Complete™ protease inhibitor cocktail, Roche Diagnostics, Mannheim, Germany). 
HPLC: acetonitrile, methanol, ethyl acetate, DMSO, orthophosphoric acid. 
Enzyme kinetic studies: KOH, anthrone reagent, H2S04, HEPES, KCl, dithiothreitol 
EDTA, MgCh, ATP, albumin, NAD, glucose-6-phosphate dehydrogenase (from 
Leuconostic mesenteroides), IDP, NADH, phophoenolpyruvate, Na2C03, malate 
dehydrogenase, SAMS (HMRSAMSGLHL VKRR) peptide and AMP. 
Grapefruit juice (GFJ), commercially processed from Ruby grapefruit (with the following 
declared nutritive contents per 100 ml: energy, 190 kJ; protein, 0.6 g; carbohydrate, 10.0 
g; total fat, 0.0 g; total dietary fibre, 0.4 g; sodium 0.0 g), was purchased from a local 
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Woolworths Groceries Stores in Durban, South Africa. No preservatives or any other 
food additives were used in this preparation (as per manufacturer's declaration). 
2.2 STUDY DESIGN AND PROCEDURE 
2.2.1 Animal experiments 
Male Wistar (Rattus novergicus) rats (200-300 g body weight), housed 5 rats per cage in 
Biomedical Resource Unit (BRU) with free access to commercial chow and drinking tap 
water, maintained on 12-hour dark/light cycle in an air-controlled room (temperature, 
25±2°C, humidity, 55±5%), were handled with humane care according to the guidelines 
of the Animal Ethics Committee of the University of KwaZulu-Natal - which approved 
the study see (Appendix 1). 
2.2.1.1 Determination ofLDso for grapefruit juice 
The median lethal dose (LDso) of grapefruit juice was determined according to a 
modified method of Lorke [350]. The rats previously fasted for 12 hours were randomly 
divided into two groups of 8 animals each. Stepwise, escalated doses of grapefruit juice 
(0, 0.25, 0.5, 1.0, 1.5, 2.0, 2.5 and 3.0 ml/kg body weight, diluted with distilled water to 
make a final volume of 1.0 ml) were administered via gastric gavage twice daily to each 
of the rats (per test group, respectively). Control group rats received 1.0 ml of distilled 
water instead of grapefruit juice. The animals in both 'test' and 'control' groups were 
allowed free access to food and drinking tap water and observed for 4 days, for signs of 
acute toxicity. These observations were recorded in a score sheet, and log-dose response 
plots were constructed, from which LDso was determined. 
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2.2.1.2 Grapefruit juice treatment 
Group A animals were divided into 4 sub-groups (designated A1-A4, respectively) of 5 
animals each, and treated with 0, 1.0, 2.0, and 3.0 ml/kg body weight of grapefruit juice, 
respectively, for 14 consecutive days. The pure grapefruit juice was diluted with a 
corresponding volume of distilled water, depending on the relevant weight, to make a 
total final volume of 1.0 ml, which was administered twice daily (Table 3). The weights 
ofthe rats were recorded daily. 
Group B animals were similarly divided into 4 sub-groups of 5 animals each (designated 
as B1-B4, respectively). Sub-groups BI and B3 were each treated with an oral dose of 3.0 
ml/kg body weight of grapefruit juice (diluted as in group A), respectively, for 14 
consecutive days. Sub-groups B2 and B4 were similarly treated with an equal volume of 
distilled water (Table 3). All the sub-groups were subsequently treated as in group A. 
Group C animals were also divided into 4 sub-groups of 5 rats each (designated C1-C4). 
Sub-groups C3 and C4 were given oral dose of 3.0 mllkg body weight of grapefruit juice 
for 14 consecutive days, while sub-groups C1 and C2 were treated with an equal volume 
of distilled water. All the sub-groups were subsequently treated as in group A, but on the 
14th day, the rats in sub-groups C2 and C4 were treated with 1.0 ml oral dose of 250 
mg/kg body weight of metformin in distilled water (Table 3). 
2.2.1.3 Glucose tolerance test 
All animals in groups A-C were starved overnight on the 13th day of treatment. Fasting 
blood glucose concentrations were determined after tail pricking and analysed by a 
portable glucometer, followed by oral administration or intraperitoneal injection (i.p) of 3 
g/kg body weight of glucose in distilled water, or in normal saline, respectively. Glucose 
solutions for oral and intraperitoneal administrations were prepared by dissolving 18.75 g 
of glucose in 50 ml of distilled water or normal saline, respectively, from which aliquot 
amounts were withdrawn to obtain a dose of 3.0 glkg body weight for each rat. 
Subsequently, blood glucose levels of the animals were monitored at times 0 30 60 and , , , 
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90 minutes in all treatment groups. Area-under-the-curve (AVC) was calculated from 
blood glucose-time curves, and the units (mmollL X minutes) presented as AVC units. 
2.2.1.4 Determination of grapefruit juice effects on glycemic index 
A group of rats was treated as in subgroups Al (controls) and A4 (test groups), 
respectively. The animals were maintained under similar conditions with unrestricted 
access to normal chow and water for 14 days. Random blood (non-fasted) samples were 
drawn at time 0 minute followed by oral administration of 3.0 g/kg body weight of 
glucose in distilled water. Blood glucose level was then monitored at 30-minute intervals 
for 90 minutes, the concentrations plotted against time, and the area-under-the-curve 
(AVC) calculated using trapezoid rule according to the FAO/WHO guidelines [351]. 
Thus Glycemic Index (GI) = AVC (GFJ/AVC(Glucose)XlOO; where AVC (GFJ) and 
AVC(Glucose) represented the AVC calculated from blood glucose-time plots in rats that 
were treated with GFJ and controls respectively. 
2.2.1 .5 peN treatment 
A separate group of rats was treated as in subgroups B2, B3 and C2, respectively with 
subcutaneous injections of pregnenolone-16alpha-carbonitrile (PCN), {17 mg/kg body 
weight (15 mg/ml in propylene glycol)} on the 10th day of treatment. Random blood 
sugar levels were determined in non-fasted rats for 90 minutes at 30 minute intervals. At 
the end of the treatment period, all the animals were euthanized by halothane overdose. 
Blood samples were collected via cardiac puncture. The livers were excised, snap frozen 
in liquid nitrogen, homogenised in phosphate buffered-saline, and stored at -180 ·C for 
further analysis. 
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2.2.1.6 Dexamethasone treatment 
Rats in subgroups A4 and C1 were treated with subcutaneous injections of 1.0 mg/kg 
body weight/day of dexamethasone for 3 consecutive days starting on 10
th 
day of 
treatment. At the end of the treatment period, the rats were euthanized by halothane 
overdose. Blood samples were collected via cardiac puncture. The livers were excised, 
snap frozen in liquid nitrogen, homogenised in phosphate buffered-saline, and stored at -
180 DC for further analysis. 
2.2.1. 7 Metformin treatment 
Metformin (500 mg tablets) purchased from a local pharmacy were crushed and dissolved 
(62.5 mg/ml) in distilled water, and the volume (ml) of metformin solution administered 
orally was calculated by dividing the weight of rat (g) by 250 g to obtain a volume 
corresponding to the dose of 250 mg/kg body weight. This means that a rat weighing 250 
g would get (250/250) 1.0 ml solution of metformin and another rat weighing 300 g 
would get (300/250) 1.2 mls of metformin solution since no more than 1.0 ml metformin 




3.1 Grapefruit juice fingerprinting 
Five aliquots of 500 ml each of GFJ were made from freshly opened containers and the 
pH adjusted to 5 (to avoid degradation of furanocoumarins) and concentrated at 40°C 
using rotary evaporator. 
3.1.1 Determination of flavonoids 
Each residue was redissolved in 1.0 ml of methanol vortexed for 1 minute and 
centrifuged at 2500 g for 15 minutes as per the modified methods of De Castro et ai, [19] 
and Ho et ai, [352]. The mixture was filtered through 0.45 11m PVDF membrane filter 
(Millipore Corp, Bedford, MA), and the supernatant analysed by high-pressure liquid 
chromatography (HPLC) equipped with photodiode array (PDA) detector and single 
quadrupole mass spectrophotometer (LC-MSD), and analysed at 285 nm. Separation was 
accomplished with a multistep linear water/acetonitrile/0.05% formic acid gradient at a 
flow rate of 0.75 ml/min. The temperature was set at 35 DC. Column used was 
Lichrospher RP-18, 250 x 4.6 internal diameter, 5 11m and Lichropher 100 RP-18, guard 
column (Merck KGaA, Darmstadt, Germany). MS parameters used were: ionisation 
mode, ES+; capillary voltage, 30 kV; extractor voltage 5V, source temperature, 100°C; 
desolvation temperature 225°C; desolvation N2 flow 465 Llh, cone N2 flow, 70 Llh; scan 
range m/z 150 and 100. 
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3.1.2 Determination of furanocoumarins 
Each of the 5 aliquots was mixed with an equal volume of ethyl acetate. Extraction was 
performed by shaking the mixture 4 times for over 30 mins. The mixture was then 
centrifuged at 3200 g for 20 minutes, and, the organic phase collected and evaporated 
under vacuum. The residue was reconstituted with 600 III of a DMSO/methanol solution 
(1:3 v/v) as previously described by De Castro et al [19]. The reconstituted residues were 
then filtered through 0.45 Ilm PVDF membrane filter (Millipore Corp, Bedford, MA). 
The extracts were analysed according to the modified method of Manthey et aI, [353]. 
For analysis in the HPLC-LC-MSD, 25 III of each sample was injected and analysed at 
310 nm under similar conditions as for the flavonoids. 
3.1.3 Component identification 
The chromatographic peaks were characterized by a combination of UV (PDA) and ESI-
MS analysis. The UV traces of the HPLC chromatograms were compared with TICs 
corresponding to [M + Ht ions of the relevant flavonoids and furanocoumarins. The [M 
+ Ht and [M = Nat peaks (if present), obtained at 20 V cone volts, were used to 
determine the molecular mass of most compounds. Fragmentation data at higher cone 
volts provided additional structural information. 
3.2 Blood glucose measurement 
Droplets of blood obtained by tail prick and mounted on glucose strips were analysed by 
portable glucometer (Ascensia Elite TM, Bayer Schering Pharma, Germany) using 
glucose oxidase method. 
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3.3 Blood lactate 
Whole blood was collected in vacutainer tubes containing sodium fluoride (NaP) and 
potassium oxalate (KO), and lactic acid was analysed by automated spectrophotometric 
method using Chern Profile 20 analyser. The L( + )-Iactic acid is selectively oxidized in the 
presence of lactate dehydrogenase (LDH) and diphosphopyridine nucleotide to form a 
light absorbing species and a reduced form of nicotine amide dinuncleotide (NADH). The 
amount of light absorbing species formed is proportional to the amount of LDH in 
plasma. 
3.4 Metformin assay 
Blood samples collected in vacutainer tubes were centrifuged and plasma samples 
deproteinized with 4 times their volume of acetonitrile before HPLC analysis. Liver 
samples were homogenized with 4 times their volume of phosphate buffered-saline, and 
deproteinized with acetonitrile, and then evaporated to dryness. Thereafter, the pellets 
were re-dissolved in 100 III of double distilled water before HPLC analysis as per the 
modified method previously described by Wang et aI, [314]. The HPLC column used was 
a 300 x 3.9 mm internal diameter, CIS JlBondpack (10 11m) (Waters, Milford, MA). The 
mobile phase consisted of 0.01 M phosphate buffer, pH 6.5, and acetonitrile in the ratio 
of 30:70. The UV detection wavelength was 236 run, and flow rate was adjusted to 1.0 
ml/min, with a metformin peak retention time of 16 minutes. 
3.5 Insulin assay 
Plasma insulin levels were analysed by Ultrasensitive Rat Insulin Enzyme-Linked 
Immunoassay kit (DRG Diagnostics, Marburg, Germany) as per manufacturer's manual. 
The assay is based on direct sandwich in which two monoclonal antibodies which were 
directed against separate antigenic determinants on the insulin molecule react with 
peroxidase-conjugated anti-insulin antibodies bound to microtitre wells upon incubation. 
Unbound enzyme labelled antibodies were removed by washing, while the bound 
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conjugates were detected by a reaction with 3,3',5,5' -tetramethylbenzidine. The reaction 
was stopped by adding 0.5 M sulphuric acid, which gave a coloured product that was 
read spectrophotometrically at 450 nm. 
3.6 Immunoblot assays 
Crude hepatocyte membrane was prepared as per the method previously described by 
Denk et al [267]. Frozen livers were homogenised in ice-cold Tris-sucrose buffer (100 
mmollL Tris, 250 mmollL sucrose, pH 7.6) using motor driven Teflfon glass 
homogeniser (Thomas Scientific, Philadelphia, PA) at 3000 rpm in the presence of 
protease inhibitor (Complete™ protease inhibitor cocktail, Roche Diagnostics, 
Mannheim, Germany). The homogenate was then ultracentrifuged at 100,000 g for 1.0 hr 
at 4°C, to obtain a membrane-enriched microsomal pellet from post nuclear supernatant. 
The pellet was then resuspended in HEPES-sucrose buffer (10 mmol/L HEPES, 300 
mmollL sucrose, pH 7.5, protease inhibitors). 
Total protein content was determined by Bradford method [354], and 50 )lg protein from 
the membrane fractions were diluted 1:4 with sample loading buffer (Table 4). The 
fractions were then heated at 95°C, cooled and then run on a 10% polyacryl amide gel 
(Table 4) with a molecular weight marker (Precision Plus Western Standard, BioRad) for 
1.0 hr at 200V at room temperature, using PowerPac Universal Power Supply {BioRad 
(Hercules, CA)}. The proteins were then transferred to Immun-Blot PVDF membrane 
(BioRad) in transfer buffer (Table 4) at 4°C, using 40 rnA supplied by PowerPac HC 
(BioRad) , and then stained with Ponceau S (Sigma-Aldrich) to ensure equal loading and 
complete transfer. The stain was then washed off with Tris-buffered saline containing 
0.1% Tween (TBS-T) (Table 4), and the blots blocked with TBS-T containing 5% dried 
milk for 2.0 hrs at room temperature. The blots were then incubated overnight at 4°C with 
rabbit anti-rat primary antibody (Alpha Diagnostics, Texas, USA), diluted 1 :5000 in 
TBS-T for 1.0 hr at 4°C. After incubation, the membrane was washed 3 times with TBS-
T and goat anti-rabbit-horseradish peroxidase secondary antibody conjugate (BioRad), 
applied in a dilution of 1 :5000 in TBS-T. Immunoreactive bands were exposed to 
autoradiography films which were developed and quantified, using ChemiDoc Image 
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Analyser Software (BioRad). To correct for variations in protein enrichment in the 
basolateral membrane, the blots were re-probed by washing twice for 10 min with TBS-
T, followed by incubation in digestion strip buffer (containing 62.5 mM Tris pH 6.8, 0.1 
M ~-mercaptoethanol and 2.0% SDS). The membranes were then washed with TBS-T 
blocked and incubated with 1 :000 dilution of rat anti-rabbit Na/K-ATPase antibody 
(Alpha Diagnostics, Texas, USA). Immunoreactive bands were semiquantitated as 
previously. 
3.7 Glycogen assay 
Hepatic glycogen content was measured by the modified method of Seifter et al [355]. 
The liver tissues were homogenised in 5 volumes of an ice-cold 4.0 M KOH solution and 
dissolved in a boiling water bath (lOO°C) for 30 minutes. The glycogen was then 
precipitated with ethanol, pelleted, washed, and resolubilized in distilled water. The 
concentration of glycogen in the liver tissues was then assayed by treatment with 
anthrone reagent [2 giL anthrone in 95% (v/v) H2S04], and the absorbance measured at 
620 nm [27]. Glycogen content was expressed as mglg liver protein. 
3.8 Glucokinase activity 
Tissues from the liver samples which had previously been snap-frozen were sampled 
from different parts of the liver and aliquoted into 100 mg per tube. Homogenates were 
prepared in buffer containing 50 mM HEPES, 100 mM KCl, 2.5mM dithiothreitol, 1 mM 
EDT A and 5 mM MgCb. Homogenates were centrifuged at 100,000 g for 1.0 hr at 4°C, 
to sediment the microsomal fraction ,(which was kept for glucose-6-phosphate assay). The 
postmicrosomal supernatant was used for the spectrophotometric measurement as per 
previously described methods of Davidson and Arion [356], and Barzila and Rosetti 
[357]. Total protein content was determined by Bradford method [354]. The formation of 
glucose-6-phosphate from glucose was coupled to oxidation by glucose-6-phosphate 
dehydrogenase and NAD+ in a continuous reaction mix containing 50 mM HEPES, 100 
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mM KCI, 2.5mM dithiothreitol, 7.5 mM MgCh, 5 mM ATP, 10 mg/ml albumin, glucose 
(0, 5, 10, 15, 25, 50 mM respectively), 0.5 mM NAD+, 4 units of glucose-6-phosphate 
dehydrogenase (from Leuconostic mesenteroides), and the equivalent of 1 mg of liver 
wet-weight. The reaction was initiated by addition of ATP, and the rate of NAD+ 
reduction recorded at 340 nm for 30 minutes at 37 ec, using Beckman DU-70 
spectrophotometer equipped with temperature controller. The enzyme activity was 
expressed as Jlmol/g liver protein/min. 
3.9 Glucose-6-phosphatase activity 
Liver content of glucose-6-phosphatase content was measured spectrophotometrically as 
per the modified method of Lange et ai, [358]. Total protein content was determined by 
Bradford method [354]. The microsomal fraction obtained from glucokinase assay and 
certified to contain no glucokinase activity was incubated with 0, 0.5, 1.0, 2.5, 5, and 10 
mM glucose-6-phosphate as previously described [356]. The reaction was carried out at 
37°C, and stopped after 30 minutes with a solution containing acid molybdate, with 2/9 
volumes of 10% SDS, and 119 volume of 10% ascorbic acid. The reaction mixture was 
then incubated at 45°C for 20 minutes, and the absorbance read at 820 nm, using 
Beckman DU-70 spectrophotometer equipped with temperature controller. The assay was 
based on the hydrolysis of glucose-6-phosphate by tissue microsomal fraction containing 
glucose-6-phosphatase. A standard curve was constructed using different concentrations 
of free phosphate, and the enzyme activity was expressed as Jlmol/minlg ofliver protein. 
3.10 Phosphoenolpyruvate carboxykinase (pEPCK) activity 
PEPCK activity was determined as per modified methods of Bentle and Lardy [359] and 
Stiffin et ai, [360]. Cytosolic fraction was obtained from homogenised liver tissues by 
centrifugation at 100,000 g for 1.0 hr at 4 ec, and the activity of enzymes measured in a 
final reaction volume of 1.0 ml, at pH 7.0, containing 50 mM sodium HEPES/KOH 
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buffer, 10.0 mM IDP, 1.0 mM MgCh, 1.0 mM dithothreitol, 0.25 mM NADH, 2.0 mM 
phophoenolpyruvate, 50 mM Na2C03 and 10 U of malate dehydrogenase (1 unit defined 
as 1 ~mol of malate produced/min/mg of liver protein). Total protein content was 
determined by Bradford method [354]. All assay components were pre-incubated for 3 
minutes. The enzyme activity was measured at 25°C and 340 nm, using Beckman DU-70 
spectrophotometer equipped with temperature controller, and expressed as ~mol of OAA 
formed/min/g ofliver protein. 
3.11 Adenosine-Monophosphate-Activated Protein Kinase (AMPK) activity 
Microsomal fraction of homogenised liver tissue was obtained by centrifugation of the 
homogenate suspended in final buffer concentration of 50 mM Tris-HCI, pH 7.5, 50 mM 
NaF, 5 mM sodium pyrophosphate, 1 mM EDTA, 10% glycerol, 1 mM dithiothreitol 
with 1 % Triton X-I00 at 4000 g for 15 minutes and the resulting supernatant removed. 
The pellet was then adjusted to 10% with polyethylene glycol and kept on ice for 10 
minutes and then centrifuged for 7000g for 15 minutes. The pellet was finally 
resuspended in 400 ~l of sample preparation buffer and ali quoted into 5 ~l portions, 
which were then assayed for AMPK activity by measuring phosphorylation of a synthetic 
peptide substrate, SAMS (His-Met-Arg-Seri-Ala-Met-Ser-Gly-Leu-His-Leu-Val-Lys-
Arg--Arg) in the presence of saturating concentrations of 5' -AMP (200 ~M), according to 
the methods of Davies et ai, [361], Foretz et ai, [362] and Sullivian et ai, [363]. Total 
protein content was determined by Bradford method [354]. The enzyme activity, 
representing cpm incorporated into SAMS peptide/min/~g of liver protein, was expressed 
as nmol/min/~g of liver protein. 
3.12 Statistical analysis 
Data obtained were presented as mean±SD. Statistical analysis was done by One-way 
ANOVA or non-parametric Mann Whitney, Student' s t-test, where applicable, using 
Graphpad Prism®, V5.0 (Graphpad Prism® Software, Inc. San Diego CA). A probability 




4.l Acute toxicity study 
No deaths or adverse effects were observed in the rats exposed to graded doses of 
grapefruit juice. There was no significant difference in the baseline and end-point animal 
weights between control and grapefruit juice-treated test rats, respectively (Figure 10). 
Net weight gain due to natural growth was 76.0±5.7 g in the control rats, compared to 
72.8±4.9 g in the grapefruit juice-treated test rats. 
4.2 Chemical constituents of grapefruit juice 
The HPLC chromatograms were dominated by peaks attributable to flavonoids, 
furancoumarins and other related compounds. The flavonoids (naringin, hesperidin, 
neohesperidin, etc) were extracted into DMSO/methanol and eluted in the early phase of 
the chromatogram (retention times, <7.5 mins) (Figure 11). In contrast, the 
furanocoumarins, which were extracted in ethyl acetate, eluted much later (retention 
times >7.5 mins) than the polar flavonoids with distinctive UV spectra (absorption 
wavelength 310 nm) easily detectable by PDA analysis (Figures 12) (Table 5). Mass 
Spectrometry fragmentations showed consistency with 6',7'-dihydroxybermottin 
structures, which were identified by fragment-ions mlz 317 (Figure 12) (Table 5). Other 
ionisation fragments were, however, unidentifiable. 
4.3 Effects of grapefruit Juice on blood glucose and glycemic Index (GI) 
4.3.1 Dose-response effects of grapefruit juice 
Glucose-response curves showed that grapefruit juice lowered plasma glucose in a dose-
dependent manner. Plasma glucose levels were significantly (p<0.05) reduced in rats 
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treated with 3.0 ml/kg body weight of grapefruit juice at 90 minutes after glucose 
challenge (Figure 13). GI was calculated from the mean±SD of AUC as explained in the 
methods (Table 6). Grapefruit juice significantly (p<O.OS) reduced GI in a dose-
dependent manner. In all subsequent experiments, 3.0 mllkg body weight of grapefruit 
juice was used as a standard dose. 
4.3.2 Fasting blood glucose 
Fasting blood glucose levels were significantly lowered (p<0.0001) in grapefruit juice-
treated 'test' rats (2.9±004 mmoIlL), compared to the control (3.7±0.39 mmol/L) rats in 
all treatment groups (Figure 14). 
4.3.3 peN-induced hyperglycemia 
Treatment of the rats with IS mg/ml of PCN in propylene glycol resulted in a significant 
(p<O.OS) rise in blood glucose levels compared to control- or grapefruit juice-treated rats, 
respectively (Figure IS). However, PCN-induced hyperglycemia was reversed by both 
metformin and grapefruit juice. Co-administration of Grapefruit juice with polyethelene 
glycol (PCN vehicle) reduced blood sugar level insignificantly compared to controls. 
4.304 Glucose tolerance 
In order to determine whether grapefruit juice affects intestinal absorption of glucose, 
GTT responses after oral and intraperitoneal administrations of glucose were compared. 
Fasting blood glucose levels were significantly reduced (p<O.OS) in grapefruit juice-
treated {3048±0o47 (oral), 3.68±0.19 (lP) mmollL} than in control 4.l2±0.34 (oral), 
4.32±0.21 (lP) mmollL} rats (Figure 16A), but the AUC calculated from GTT after the 
animals were challenged with 3.0 g/kg body weight of glucose either orally or 
intraperitoneally, showed no significant difference in both the control and grapefruit-
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treated test animals, respectively (Figures 16B and C). All subsequent experiments were, 
therefore, performed with intraperitoneal injection of glucose. 
When rats were challenged with intrapetoneal injection of 3.0 glkg body weight of 
glucose, grapefruit juice alone (495±77 AVC units), or in combination with metformin 
(491±61 AVC units), significantly (p<0.05) lowered blood glucose levels compared to 
control (636±59 AVC units) animals, but insignificantly (p>0.05) compared to metformin 
(543±96 AVC units) (Figures 17 A and 17B). Metformin alone lowered blood glucose 
levels compared to control animals, but the difference was not statistically significant. 
4.4 Effects of Grapefruit juice on plasma insulin 
There was no significant difference in fasting (0 hr) or 1.5-hour plasma insulin levels 
among all treatment groups (Figure 18), suggesting that neither metformin nor grapefruit 
juice significantly influenced insulin response in the rats after glucose challenge. 
Similarly, PCN did not affect insulin response. 
4.5 Effect of grapefruit juice on hepatic glucose homeostasis 
4.5.1 Hepatic glycogen content 
Grapefruit juice- (409±25 mg/g of liver tissue), dexamethasone- (395±27 mg/g of liver 
tissue) or dexamethasone and grapefruit juice- (439±35 mg/g of liver tissue) as well 
PCN- (372±27 mg/g of liver tissue) treated animals had significantly (p<0.05) increased 
glycogen levels compared to control (288±14 mg/g ofliver) rats, respectively. Metformin 
(290±15 mg/g of liver tissue) did not change glycogen levels compared to controls, but 
when co-administered with PCN, significantly (p= 0.0079) reduced PCN-induced 
glycogen storage (Figure 19). 
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4.5.2 Glucokinase activity 
Hepatic glucokinase activity was measured in vitro in liver samples which had previously 
been snap-frozen. The activity of glucokinase obeyed Michaelis-Menten kinetics when 
plotted against substrate concentration (Figure 20). The data was then transformed into 
Eadie-Hofstee plots [356], which were used to calculate Km and V max, respectively. Rats 
treated with dexamethasone (344 ~M) and metformin (369 ~M) had parallel slopes, 
suggesting comparable Km values, while grapefruit juice-treatment significantly (p<0.05) 
reduced Km (144 ~M), even in the presence of dexamethasone (269 ~M), compared to 
control rats (308 ~M), respectively. Metformin alone (369 ~M) or with PCN (351 ~M) 
had no significant effect on Km compared to control rats, respectively. Grapefruit juice 
treatment (26.65± 1.11 ~mo1/g of liver tissue/min) doubled the V max compared to control 
(13.56±0.72 ~mol/g of liver tissue/min) rats, and decreased V max when co-administered 
with dexamethasone (16.83±0.36 ~mol/g of liver tissue/min), compared to 
dexamethasone alone (18.86±0.476 ~mo1/g of liver tissue/min), respectively. Metformin 
treatment (20.04±0.406 ~mol/g of liver tissue/min) significantly (p<0.05) increased V max 
compared to control rats, but had no significant effect on V max when co-administered with 
PCN (13.72±0.876 ~mol/g of liver tissue/min), compared to PCN alone (11.51±I1.51 
~mol/g of liver tissue/min), (Table 7). Linear regression analysis showed significant 
correlation between substrate concentration and glucokinase activity in grapefruit juice-
(r2= 0.8535), grapefruit juice with dexamethasone- (r2 = 0.9137), dexamethasone-(r2 = 
0.8460) and metformin- (r = 0.8835) treatments respectively (Figure 21) (Table 7). 
Calculations of V max/Km ratio suggested that glucokinase activity is increased in the order 
of decreasing magnitude following treatment with grapefruit juice, grapefruit juice with 
dexamethasone, dexamethasone and metformin compared to controls, respectively (Table 
7). PCN treatment with or without metformin did not increase glucokinase activity 
compared to controls (Table 7). 
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4.5.3 Glucose-6-phosphatase (G6Pase) activity 
Hepatic glucose-6-phosphatase activity was measured in microsomal fractions of the liver 
tissues (as prepared in the glucokinase assay). The activity of glucose-6-phosphatase 
similarly obeyed Michaelis-Menten kinetics when plotted against substrate concentration 
(Figure 22). The data was then transformed into Eadie-Hofstee plots [356], which were 
used to calculate Km and V max, respectively. Both dexamethasone- (Km = 1.705 mM; V max 
= 23.l9±0.577 ~mol/min/g liver tissue) and PCN- (Km = 1.299 mM; Vmax = 23.84±1.1D2 
~mol/min/g liver tissue) treatments significantly (p<0.05) increased glucose-6-
phosphatase activity, compared to controls (Km = 2.068 mM; V max = 13.4±0.45 
~mol/minlg liver tissue). Metformin administered alone (Km = 2.32 mM; Vmax = 
13.85±0.34 ~mol/min/g liver tissue) or concurrently with PCN (Km = 2.26 mM; Vmax = 
13.4±0.80 ~mol/minlg liver tissue), significantly (p<0.05) reduced glucose-6-phosphatase 
activity compared to PCN. Grapefruit juice (Km = 2.29 mM; Vmax = 14.02±0.45 
~mol/min/g liver tissue) exhibited similar effects to metformin on the activity of glucose-
6-phosphatase, but slightly decreased dexamethasone-induced activity (Figure 22), (Table 
8). Linear regression analysis showed a strong correlation coefficient between substrate 
concentration and enzyme activity in dexamethasone-treated with (r2 =0.9219) or without 
(r2 = 0.9400), grapefruit juice, and in metformin-treated animals compared to control (r2 
= 0.8412) rats, respectively (Figure 25). The correlation coefficient was poor in grapefruit 
juice- (r2 = 0.7800) and metformin (with PCN)-treated rats (r2 = 0.6050), respectively, 
suggesting a down-regulation/repression of enzyme activity. Calculations of V max! Km 
ratio suggested that glucose-6-phosphatase activity increased following treatments with 
PCN, dexamethasone, and grapefruit juice with dexamethasone (in the order of 
decreasing magnitude) but not grapefruit juice, metformin or metformin with PCN, 
compared to controls, respectively (Table 8). 
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4.5.4 Phosphoenolpyruvate carboxy kinase (pEPCK) 
The activity of PEPCK similarly obeyed Michaelis-Menten kinetics when plotted against 
substrate concentration (Figure 24). The data was then transformed into Eadie-Hofstee 
plots [356], which were used to calculate Km and V max, respectively. Grapefruit juice (Km 
= 1.55 mM; V max = 12.44±0.41 Ilmol/g of liver tissue/ min) did not significantly affect 
the activity of PEPCK compared to controls (Km = 1.379 mM; Vmax = 13.73±0.399 
Ilmol/g of liver tissue/ min), but significantly (p<0.05) reduced (Km = 2.78 mM; V max = 
10.72±0.3630 Ilmol/g of liver tissue/ min) dexamethasone-induced effects (Km = 0.738 
mM; Vmax = 26.78±0.41 Ilmol/g of liver tissue/ min) on PEPCK activity. Similarly, 
metformin alone (Km = 1.615 mM; Vmax = 12.1±0.481 Ilmol/g of liver tissue/ min) did 
not significantly affect PEPCK activity compared to controls, but significantly (p<0.05) 
opposed (Km = 1.398 mM; Vmax = 14.32±0.749 Ilmol/g of liver tissue/ min) PCN-induced 
(Km = 0.7151 mM; Vmax = 27.77±0.81 Ilmol/g of liver tissue/ min) effects on PEPCK 
activity when administered concurrently with PCN. Dexamethasone and PCN treatments 
significantly increased PEPCK activity compared to controls (Table 9). Linear regression 
analysis showed significant correlation between PEPCK activity and substrate 
concentrations in dexamethasone- (r2 = 0.9162) and PCN- (r2 = 0.9506) treated animals 
compared to control groups (r2 = 0.8141), respectively, but this correlation was reduced 
in the presence of grapefruit juice (r2 = 0.782) and metformin (r2 = 0.7716) respectively 
(Figure 25) (Table 9). Grapefruit juice alone (r2 = 0.8817), or metformin alone (r2 = 
0.8337), showed relatively poor correlation between the enzyme activity and substrate 
concentration, suggesting a repression of PEPCK activity by both. Calculations of V max! 
Km ratio suggested that PEPCK activity increased in the order of decreasing magnitude 
following treatments with PCN, dexamethasone, but not grapefruit juice or metformin, 
compared to controls, respectively. Grapefruit juice and metformin appeared to decrease 
dexamethasone- and PCN- induced increases in PEPCK activity, compared to controls, 
respectively (Table 9). 
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4.5.5 Hepatic Adenosine Monophosphate Activated Protein kinase (AMPK) 
Hepatic AMPK activity similarly obeyed Michaelis-Menten kinetics when plotted against 
substrate concentration (Figure 26). The data was then transformed into Eadie-Hofstee 
plots [356], which were used to calculate Km and V max, respectively. Grapefruit juice 
alone (Km = 0.02 mM; Vmax = 96.44±2.47 nmoll min/llg of liver tissue), or in 
combination with dexamethasone (Km = 0.0321 mM; Vmax = 84.71±3.949 nmoll minlllg 
of liver tissue), significantly (p<0.0001) increased AMPK activity in the 'test' compared 
to control (Km = 0.146 mM; Vmax = 7.442±0.411 nmoll min/llg of liver tissue) rats 
(Figures 26 and 27). Similarly dexamethasone alone (Km = 0.0194 mM; V max = 
89.94±4.75 nmollminlllg of liver tissue), or metformin alone (Km = 0.0411 mM; Vmax = 
79.0±3.887 nmol/minlllg of liver tissue) significantly (p<0.0001) increased AMPK 
activity compared to controls. PCN treatment with (Km = 0.0217 mM; Vmax = 93.74±6.55 
nmoll minlllg of liver tissue) or without (Km = 0.017 mM; V max = 89.75±1O.08 
nmollminlllg of liver tissue) metformin, significantly (p<0.05) increased AMPK activity 
compared to controls. Linear regression analysis of Eadie-Hofstee plots showed 
significant (p<0.05) positive correlation between substrate concentration and the activity 
of AMPK in grapefruit juice (r2 =0.966), dexamethasone with (r2 = 0.8898) or without (r2 
= 0.9017) grapefruit juice, PCN with metformin (r2 = 0.8283), and metformin alone (r2 = 
0.8557) (Figure 27). Poor correlation coefficient was observed between substrate 
concentration and the activity of AMPK in rats treated with PCN alone (r2 = 0.6782). 
Calculations of V maxi Km ratio suggested that AMPK activity increased in the order of 
decreasing magnitude following treatments with dexamethasone, PCN with metformin, 
grapefruit juice, metformin, PCN and dexamethasone with grapefruit juice, compared to 
controls, respectively (Table 10). 
4.6 Effect of grapefruit juice on metformin-induced lactic acidosis 
Blood lactic acid levels were significantly higher (p=0.0079) in rats that were treated with 
either metformin alone (5.38 ± 2.53 mmoIlL), or metformin in combination with 
grapefruit juice (8.31 ±2.5 mmollL), than in control (2.54 ± 0.7 mmollL) rats, 
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respectively. However, lactate levels after treatment with grapefruit juice alone (2.81 ± 
1.4 mmollL) were similar to those of control rats, but significantly lower than in the 
combination of grapefruit juice and metformin, respectively (Figure 28). 
4.7 Effect of grapefruit juice on hepatic metformin uptake 
Grapefruit juice- and PCN- treated rats had significantly (p<0.05) higher metformin 
levels in their liver tissues than the control rats (metformin only). Plasma metformin 
levels were lower in control rats than in the treated groups, but the difference was not 
statistically significant (Table 11). However, the plasma: liver ratio of metformin was 
significantly (p<0.05) reduced in the grapefruit juice- and PCN-treated groups, compared 
to controls. Linear regression analysis showed significant correlation between liver tissue 
metformin concentrations and plasma lactic acid levels in both control (p= 0.0122; r2 = 
0.9080) and grapefruit juice-treated ' test' rats (p= 0.0005; r2=0.9893) (Figure 29). The 
correlation coefficient was, however, stronger in the latter group. PCN treatment showed 
similar correlation co-efficient between blood lactate levels and liver metformin as with 
grapefruit juice treatment (data not shown on graph for clarity). Surprisingly, no 
correlation was observed between plasma lactate and metformin levels in both groups. 
4.8 Effect of grapefruit juice on hepatic expression of OCTl protein 
Hepatocyte membrane fractions were separated by SDS-PAGE and transferred to PVD 
membranes. Ponceau S stains of the membrane before probing indicated that the protein 
bands were clearly separated and transferred (Figure 30). Similar staining of the gel 
confirmed that no proteins remained on it. Immunoblot assay showed the expression of a 
distinct band of 66 kDa protein, corresponding to rOctl protein, in response to different 
agonists (Figure 31). Densitometry scans expressed as a percentage of the controls 
showed that dexamethasone (80.6±40.28%) significantly (p<0.000 1) downregulated 
rOctI expression, compared to grapefruit juice (285.6±33.4%), PCN (260±25.7%), or 
metformin and PCN (275±48.4%), respectively (Figure 30). However, grapefruit juice 
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treatment significantly (p<0.05) reversed dexamethasone-induced down-regulation of 
rOctI (165.4±26.4%) (Figure 32). Metformin alone did not up-regulate rOctI expression 




A commercial preparation of grapefruit juice was used in this study in order to guard 
against variations in the chemical constituents/active ingredients due to harvesting time -
which may influence ripening of the fruits [20]. The method of processing has previously 
been reported to influence the relative abundance of bioactive constituent compounds 
[19]. Batch processed commercial preparations would, therefore, be expected to 
minimize such variations. No signs of toxicity, or significant difference in weight gain 
were noted between grapefruit juice-treated (76.0±5.7 g) and control (72.8±4.9 g) rats, 
respectively, suggesting that grapefruit juice did not influence the natural growth of the 
animals (Figure 10). 
HPLC and LC-MSD analysis showed that the grapefruit extract used in this study 
contained flavonoids and furanocourmarins (Figures 11, 12 and 13). Mass spectrometry 
fragmentations showed consistency with 6',7'-dihydroxybergamottin as well as 7-
geranyloxycoumarin structures which were identified by fragment ions m/z 317 and 
298.9, respectively (Figures 12 and 13). Even though other ionisation fragments were not 
identifiable, their fragmentation patterns were consistent with the presence of flavonoids 
(naringin, hesperidin, neohesperidin etc) and furancoumarins (bergamottin, 6',7'-
epoxybergamottin etc) respectively [353] (Table 5). Some of the fragment ions could 
have been part of dimmers of these chemical entities making direct identification of 
molar masses difficult. 
Grapefruit juice lowered blood glucose levels in a dose-dependent manner (Figure 13) 
after the rats were challenged with 3.0 g/kg body weight of glucose, which corresponded 
to concomitant significant reduction in GI index (Table 6). Glycemic index is defined as 
"blood glucose response to a test food consumed by an individual under standard 
conditions, and expressed as a percentage of the AUC following consumption of 
reference food consumed by the same person on a different day" [351, 364]. By this 
definition, the test food in this study was the normal chow, and the reference food was 
glucose, which is normally assigned a GI of 100. Other carbohydrates were not used as 
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they would have interfered with glucose homeostasis. In this study, a maximum of 3.0 
mllkg body weight of glucose was administered to rats which weighed 316.4±16.3 gat 
end-point (Figure 10). The grapefruit juice used had a declared carbohydrate content of 
0.6 g/100 ml. This implies that at a mean weight of 316 g, each rat was dosed with a 
maximum of 0.948 ml (948 Jll) of grapefruit juice which contained an equivalent 6 mg of 
carbohydrate. Since 24 hrs had elapsed between the last grapefruit juice dosing and the 
time the test was done, it was highly unlikely that the negligible carbohydrate ·content of 
grapefruit juice could have influenced glycemic index calculation. Higher doses of 
grapefruit juice were not possible to administer since only a maximum of 1.0 ml was 
permissible orally by the weight of the rats. 
Grapefruit juice significantly (p<0.05) lowered fasting blood glucose levels (Figure 14) 
without any significant effect on fasting or 1.5-hour post-glucose insulin level (Figure 18) 
in grapefruit juice-treated test (2.9±0.4 mmollL), compared to control (3.7±0.39 mmollL) 
rats. This observation, therefore, suggests that grapefruit juice or its constituent 
chemicals, could be mediating hepatic glucose homeostasis, rather than pancreatic insulin 
release. The study by Fujioka et ai, [17] reported that grapefruit juice improved insulin 
resistance in patients with metabolic syndrome, with or without diabetes, but in this 
study, normal non-diabetic rats were used. In any case, the phenomenon of weight 
reduction associated with grapefruit, suggests that grapefruit effects on glucose control is 
more complicated than is currently understood, and may involve control of glucose and 
lipid metabolism in other organs, such as the intestines, liver, skeletal muscle and even 
adipose tissue. The current study, therefore, supports the hypothesis that grapefruit juice 
consumption promotes efficient glucose utilisation, and may, therefore, be beneficial in 
the management of metabolic syndrome. 
peN administration significantly elevated blood sugar, compared to control or grapefruit 
juice-treated rats, respectively (Figure 15). This elevation of blood sugar was, however, 
reversed by concomitant administration of metformin or grapefruit juice respectively. 
peN is a known hepatic microsomal enzyme inducer [338], but its effects on blood 
glucose control have hardly been investigated. A study by Szabo et ai, [365] reported that 
peN-induced marked changes in blood glucose in rats; and another study by 
Kourounakis et ai, [356] reported peN induced depletion of hepatic glycogen. However, 
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in the present study, when liver glycogen content was measured in rats previously treated 
with PCN, significant (p<0.05) increase (372±27 mg/g of liver tissue) in hepatic glycogen 
content was observed compared to control rats (288±14 mg/g of liver tissue) (Figure 19). 
A recent study by Kodama et ai, [338], reported that PCN activates PXR, which mediates 
down-regulation of glucagon stimulated gluconeogenic and glycogenolytic rate limiting 
step enzymes (glucose-6-phosphatase (G6Pase) and phosphoenolpyruvate carboxykinase 
(PEPCK1). However, in this study, glucose-6-phosphatase activity increased (Km = 1.299 
mM; Vmax = 23.84±1.102 J.lg/mollminlg liver tissue) significantly (p<0.05) in PCN-
treated compared to control (Km = 2.068 mM; Vmax = 13.4±0.45 J.lmollminlg liver tissue) 
rats (Figures 22 and 23). PCN-induced increased activity of glucose-6-phosphatase was, 
however, abolished in the presence of metformin (Km = 2.32 mM; V max = 13.85±0.34 
J.lmollminlg liver tissue) (Table 8). Likewise, PEPCK activity increased in PCN-treated 
(Km = 0.7151 mM; Vmax = 27.77±0.81 J.lmol/g of liver tissue/ min) compared to control 
(Km = 1.379 mM; Vmax = 13.73±0.399 J.lmol/g of liver tissue/ min) rats (Figures 24 and 
25). PCN-induced increased activity of PEPCK was significantly (p<0.05) reversed by 
metformin treatment (Km = 1.398 mM; Vmax = 14.32±0.749 J.lmol/g of liver tissue/ min) 
(Table 9). However, PCN did not significantly affect the activity of glucokinase (Km = 
422 J.!M; Vmax = 11.51±0.83 J.lmol/minlg of liver tissue), compared to the controls (Km = 
308 J.lM; V max = 13.56±0.72 J.lmollmin/g of liver tissue), despite the fact that it increased 
hepatic glycogen content (Table 7). Glucokinase is a regulatory enzyme controlling the 
first step in hepatic glycolytic pathway, and the calculated V max/Km ratios suggest that 
PCN (27.3) repressed glucokinase activity, compared to the controls (44.0) (Table 7). It 
is, therefore, possible that in this in vivo model, unlike the study of Kodama et al [338], 
which was done in vitro, PCN causes hyperglycemia by up-regulation of key 
gluconeogenic enzymes (G-6-Pase, and PEPCK), and concomitantly repressing 
glucokinase activity. This could be through modulation of key enzymes controlling the 
upstream regulators of G-6-Pase, PEPCK as well as glucokinase expression, such as 
AMPK. That metformin opposed PCN-mediated effects on both G-6-Pase and PEPCK 
suggests that there could be a common regulatory pathway that controls the activities of 
these enzymes. 
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Metformin is known to lower blood sugar by, amongst other mechanisms, up-regulation 
of AMPK, which inhibits the expression of PEPCKI and G6Pase, respectively [334, 
335]. Metformin did not affect hepatic glycogen content (290±15 mg/g of liver tissue) 
(Figure 19) but marginally increased glucokinase activity (Km = 396 IlM; V max = 
20A±OA06 Ilmol/min/llg of liver tissue) compared to controls (288±14 mg/g of liver 
tissue), (Km = 308 IlM; Vmax = 13.6±0.72 Ilmol/min/llg of liver tissue) respectively, 
(Figures 21 and 22), (Table 7), despite opposing PCN-induced activation of both G6Pase 
and PEPCK (Tables 8 and 9). However, metformin alone (Km = 0.0411 mM; V max = 
79.0±3.887 nmollminlllg of liver tissue), or in combination with PCN (Km = 0.0217 mM; 
Vmax = 93.74±6.55 nmoll min/llg of liver tissue), significantly (p<0.0001) increased 
AMPK activity compared to controls (Km = 0.146 mM; Vmax = 7A42±OAll nmoll 
minlllg of liver tissue) (Figures 26 and 27) (Table 10). It is important to point out at this 
stage that, PCN is known to activate OCTl, which transports metformin into hepatocytes 
[314]. It is, therefore, logical to speculate that PCN enhanced hepatic uptake of 
metformin, which inhibited gluconeogenic/glycogenolytic pathways through upregulation 
of AMPK, which may, therefore, suggest that PCN-induced hyperglycemia may be 
mediated by up-regulation of G6Pase and PEPCK, which is abolished in the presence of 
metformin. However, there may be many other nuclear receptors regulating synthesis of 
hepatic gluconoegenic/glycogenolytic enzymes, which are PCN responsive. Such factors 
may up-regulate enzymes like glycogen synthase, or down-regulate glycogen 
phosphorylase, which may account for the observed increase in hepatic glycogen storage 
in the present study. These observations, however, need to be verified by hepatic gene 
expression of these enzymes to confirm whether they occur at gene transcription level, or 
at post-translation processing of the relevant proteins, or both. However, preliminary data 
available so far seem to suggest the latter [331, 332, 333, 334, 336]. 
Grapefruit juice improved glucose tolerance and exerted metformin-like effect on blood 
sugar levels (Figure 16). Fasting blood glucose levels were significantly (p<0.05) lower 
in grapefruit juice treated {3A8±OA7 (oral), 3.68±O.l9 (IP) mmoIlL}, than in control 
{4.l2±0.34 (oral), 4.32±0.21 (IP) mmoI/L}rats, respectively, prior to administration of 
3.0 g/kg body weight of glucose (Figure 16). However, blood glucose-time response 
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curves constructed showed no significant difference between oral and intraperitoneal 
administration of glucose (Figure 16B and C). This suggests that grapefruit juice 
administration did not significantly affect oral absorption of glucose, taking into account 
the known effect of grapefruit juice on intestinal glucose metabolism, and that potential 
hypoglycaemic effect of grapefruit juice could be due to an influence on hepatic 
metabolism of glucose. Glucose tolerance test was done with metformin as a 'reference 
drug'. Grapefruit juice alone (495±77 AVe units), or in combination with metformin 
(491±61 Ave units), significantly (p<0.05) lowered blood glucose levels in the 'test' 
compared to 'control' (636±59 AVe units) animals, but insignificantly (p>0.05) 
compared to metformin (543±96 AVe units) (Figures 17A and B). Metformin alone (at a 
dose of 250 mg/kg body weight) lowered blood glucose levels compared to controls, but 
less than grapefruit juice- or grapefruit juice in combination with metformin-treated rats, 
respectively, but the difference was not statistically significant. Perhaps more profound 
differences could have been observed with an increased dose of metformin, since we 
previously noted a dose-dependent reduction in blood glucose levels with grapefruit juice 
alone (Figure 13). These observations, therefore, suggest that grapefruit juice could be 
exhibiting metformin-like effects on hepatic regulation of blood glucose. Metformin is a 
widely-used antidiabetic agent that lowers blood glucose levels by inhibiting hepatic 
gluconeogenesis, enhancing hepatic and skeletal muscle glucose uptake, and reducing 
intestinal glucose absorption [344]. It is unlikely that metformin alone, or in combination 
with grapefruit juice, could have interfered with glucose absorption in this study, since 
glucose was administered intraperitoneally. 
Grapefruit juice (409±25 mg/g ofliver) significantly (p<0.05) increased hepatic glycogen 
content compared to controls (288±14 mg/g of liver) (Figure 19). Metformin alone 
(290± 15 mg/g of liver) did not significantly change hepatic glycogen content compared 
to controls but when co-administered with peN, significantly (p = 0.0079) reversed 
PeN-induced glycogen storage in the liver (Figure 18). Grapefruit juice significantly 
(p<0.05) increased hepatic glucokinase activity (Km = 144 IlM; V max = 26.65±1.11 
Ilmol/min/g of liver tissue) compared to controls (Km = 308 IlM; V max = 13.56±0.72 
Ilmollminlg of liver tissue), but decreased (Km = 2.69 IlM; V max = 16.83±0.36 
Ilmol/min/g of liver tissue) the enzyme activity when co-administered with 
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dexamethasone, compared to dexamethasone alone (Km = 344 11M; Vmax = 18.66±0.46 
Ilmol/min/g of liver tissue) (Figures 20 and 21). Metformin, on the other hand, had only a 
modest increase in glucokinase activity (Table 7). It is not possible to determine whether 
increased glucokinase activity in response to grapefruit juice treatment corresponded to 
increased hepatic glycogen content since linear regression analysis of glucokinase 
activity and hepatic glycogen content, showed no positive correlation. It is possible that 
increased glycolytic flux in this respect translated into glucose expenditure in energy 
generation (ATP synthesis), or other cellular anabolic reactions such as lipogenesis. 
However, grapefruit juice alone (Km = 2.29 mM; Vmax = 14.02±0.54 Ilmollminlg liver 
tissue) or metformin alone (Km = 2.23 mM; V max = 13.85±0.348 Ilmollmin/g liver tissue) 
significantly (p<0.05) reduced glucose-6-phosphatase activity, compared to 
dexamethasone (Km = 1.705 mM; Vmax = 23.19±0.58 Ilmol/minlg liver tissue), and PCN 
(Km = 1.299 mM; Vmax = 23.84±1.10 Ilmollmin/g liver tissue) respectively (Figures 22 
and 23). When both grapefruit juice and metformin were co-administered with 
dexamethasone (Km = 1.738 mM; Vmax = 19.26±0.41 Ilmollminlg liver tissue) and PCN 
(Km = 2.26 mM; Vmax = 13.34±0.8 Ilmollmin/g liver tissue), respectively, glucose-6-
phosphatase activity was similarly reduced compared to either dexamethasone or PCN 
alone, respectively (Table 8). Similarly grapefruit juice (Km = 1.55 mM; V max = 
12.44±0.41 Ilmol/minlg liver tissue) did not have any significant effect on PEPCK 
activity compared to controls (Km = 1.379 mM; V max = 13.37±0.399 Ilmollmin/g liver 
tissue), but significantly (p<0.05) reduced (Km = 2.78 mM; Vmax = 1O.72±0.363 
Ilmollminlg liver tissue) dexamethasone-induced increase in PEPCK activity (Km = 
0.0738 mM; Vmax = 26.78±0.41 Ilmollminlg liver tissue) (Figures 24 and 25). Likewise, 
metformin alone (Km = 1.615 mM; Vmax = 12.l±0.481 Ilmollmin/g liver tissue) did not 
significantly affect PEPCK activity compared to controls, but significantly (p<0.05) 
antagonised (Km = 1.398 mM; V max = 14.32±0.749 Ilmollminlg liver tissue) PCN-induced 
(Km = 0.7151 mM; Vmax = 27.77±0.81 Ilmol/min/g liver tissue) increase in PEPCK 
activity when both metformin and PCN were administered concurrently (Figures 24 and 
25), (Table 9). A recent study by Purushotham et aI, [29] reported that naringenin, a 
naringin aglycone commonly found in grapefruit juice (Figure 2) (Table 1), suppressed 
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hepatic glucose production from hepatoma (Fao) cells, and that like metformin, decreased 
cellular ATP levels without decreasing cellular toxicity. Previously, lung et al, [27] 
reported that hesperidine and naringin reduced blood glucose in diabetic mice by 
elevating hepatic glucokinase and glycogen concentration, by suppressing the activities 
of glucose-6-phosphatase and PEPCK, respectively. These studies, like the present one, 
confirm that grapefruit juice or its constituent chemicals, have metformin-like regulatory 
properties on hepatic metabolism of glucose by suppressing or activating the key 
gluconeogenic or glycolytic enzymes reducing blood glucose levels. However, the earlier 
studies, unlike the present one, were either done on diabetic mice, or used purified 
grapefruit juice ingredients in vitro. It has to be pointed out that similar attempts at 
determining constituent chemicals of grapefruit that are responsible for the inhibition of 
intestinal CYP3A4 gave inconclusive evidence, owing to the diversity of the composition 
of such chemicals in the grapefruit juice. 
It is not clear from these studies [27, 29] whether naringenin, or hespiridine, regulates the 
activities of these enzymes via direct chemical interaction or regulation of gene 
transcription/translation of the corresponding proteins. However, the current study 
confirms that, like metformin, grapefruit juice alone (Km = 0.0298 mM; V max 
96.44±2.478 nmol/min/g liver tissue) or in combination with dexamethasone (Km 
0.0321 mM; Vmax = 84.71±3.949 nmol/min/g liver tissue), significantly (p<0.0001) 
increased AMPK activity in the 'test' compared to 'control' (Km = 0.146 mM; Vmax = 
7.442±0.411 nmol/min/g liver tissue) preparations (Figures 26 and 27) (Table 10). This 
suggests that down-regulation of glucose-6-phosphatase and PEPCK activities observed 
with grapefruit juice could be as a result of increased AMPK activity, which, therefore 
down-regulated the expression of glucose-6-phosphatase and PEPCK respectively. 
The present study therefore provides the first evidence that anti-obesity effects of 
grapefruit juice consumption may be mediated by AMPK which may have 
downregulated key gluconeogenic enzymes. AMPK-mediated effects of grapefruit juice 
may be short-term (via phosphorylation of these enzymes) or long-term (via regulation of 
gene expression of these enzymes) (Figure 33). In the present study, the rats were treated 
with grapefruit juice for 14 days which was long enough to induce chronic effects such as 
gene expression of AMPK and its downstream targets. AMPK activation in the liver 
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leads to metabolic consequences (such as inhibition of gluconeogenesis) that are 
beneficial to diabetic patients. Grapefruit juice induction of increased AMPK activity 
may as well establish grapefruit juice or its chemical constituents as one of the AMPK 
modulators which are currently being vigorously pursued as potential anti-diabetic and 
anti-obesity agents. 
Metformin treatment caused a significant (p=O.0079) increase in blood lactic acid levels, 
compared to control rats (5.38±2.53 versus 2.54±O.7 mmollL, respectively) (Figure 28). 
There was no significant difference in blood lactate levels in grapefruit juice-treated rats 
(2.8±1.4 mmollL) and control animals. However, when metformin was administered to 
rats which had been previously treated with grapefruit juice, there was a significant 
increase (p<O.05) in lactate levels (8.3±2.5 mmoIlL), compared to the control, grapefruit 
juice- or metformin alone-treated rats, respectively (Figure 28). Metformin-associated 
lactic acidosis is commonly seen in patients with renal dysfunction, congestive heart 
failure, and acute or chronic metabolic acidosis [317, 346, 347, 348]. Intestinal lactate 
production in the absence of conditions associated with tissue hypoxia has previously 
been described [327]. In the experimental animal model used in this study, lactate could 
not have been produced from the intestines since glucose was administered 
intraperitoneally. Experimental animal studies have also shown that metformin does not 
cause a net increase in lactate production in other tissues such as muscle, fat, brain, and 
skin [325, 326], hence, the increase in lactate levels observed in the present study could 
only have been of hepatic origin. In any case, lactate produced from the intestines is 
likely to be rapidly removed from circulation by hepatic metabolism. 
Under normal circumstances, hepatic clearance of lactate by the liver maintains lactate 
levels below 5 mmollL. Renal impairment causes metformin-associated lactic acidosis, 
due to reduced clearance, causing metformin to build up in the body. Metformin is not 
metabolised in the body, but solely excreted by the kidneys. However, other conditions 
such as metformin overdose, may also lead to lactic acidosis in the absence of renal 
failure [349]. Such conditions may thus be described as leading to metformin-induced 
lactic acidosis. In the present study, normal, non-diabetic rats were used, and, therefore, 
the increased lactate production can only be attributed to the dose of metformin 
administered, and its accumulation in hepatocytes. Clinically, lactic acidosis has 
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previously been reported in patients without chronic renal failure, who took metformin 
[343], contrary to the popular belief that metformin, unlike other biguanides, does not 
cause lactic acidosis. The present study, therefore, provides direct in vivo evidence that 
metformin can cause lactic acidosis without the commonly-associated co-morbidities. 
The results presented here surprisingly show an enhanced lactate production when rats 
that had previously been exposed to grapefruit juice were treated with metformin, 
compared to the rats that were given metformin alone (Figure 28). Rats that were treated 
with grapefruit juice alone had similar lactate levels to the controls, suggesting that 
grapefruit did not induce tissue hypoxia, or cause metabolic disturbances that may have 
led to increased lactate levels. It may, therefore, be concluded that grapefruit juice, just 
like PCN, facilitated metformin uptake by hepatic tissue because, even though plasma 
metformin levels in grapefruit juice-treated and control rats were comparable, metfromin 
concentrations in the liver tissue was significantly higher in grapefruit juice- and PCN-
treated 'test' than in the 'control' rats (Table 11). Plasma: liver metformin ratio was 
significantly (p<O.05) elevated in PCN- and grapefruit juice-treated rats, respectively. 
Linear regression analysis showed stronger correlation between metformin concentration 
in the liver, and plasma lactate levels in grapefruit juice- and PCN-treated 'test' animals 
than in the control rats (Figure 29). No such correlation was apparent between plasma 
lactate and metformin concentrations in both groups. These results are in tandem with 
those of Wang et aI, [314], who showed that lactic acidosis is mainly caused by intra-
hepatic metformin, which inhibits lactate metabolism in the liver. In view of this, it is, 
therefore, not surprising that Stades et aI, [367] found no positive correlation between 
plasma metformin concentration and lactic acid. Metformin is a known specific substrate 
of organic cation transporter protein (OCTI), which is mainly expressed in the liver, and 
to a lesser extent, in the kidney [225, 241, 242, 243]. Wang et aI, [314] have clearly 
demonstrated that OCTI mediation of hepatic uptake of metformin is linked to the 
development of lactic acidosis in rats. This, therefore, suggests that grapefruit juice could 
be up-regulating or stimulating the activity of OCTl, which enhances liver uptake of 
metformin. 
The expression of rOctI in hepatocytes in response to grapefruit juice, a known inducer 
PCN and down-regulator, dexamethasone, were further investigated. rOctI is a known 
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membrane protein, and the 50 Ilg protein loaded on the SDS-PAGE gel was deemed to be 
microsomal membrane protein-rich. The Ponceau S staining (Figure 30) confirmed equal 
loading and successful transfer of the proteins from the gel to the membrane. 
Immunoreactive bands detected by immunoblot assay, identified a prominent 66kDa 
protein corresponding to rOctI, to be expressed in rat liver microsomal protein fraction 
(Figure 31). When the membrane was stripped and re-probed by rat anti-rabbit Na/K-
ATPase monoclonal antibody, prominent bands were identified in all the membrane 
fractions separated by SDS-PAGE, suggesting equal enrichment with membrane 
fractions. Na/K-A TPase is a membrane protein commonly found in mammalian cells. 
Densitometry scans of the immunoreactive bands showing steady-state protein levels 
expressed as a percentage of the controls, showed that dexamethasone (80.6±40.28%) 
significantly (p<0.0001) down-regulated rOctl expression, compared to grapefruit juice 
(285.6±33.4%), PCN 260±25.7%), or metformin and PCN (275±48.4%), respectively 
(Figure 32). However, grapefruit juice treatment significantly (p<0.05) reversed 
dexamethasone-induced down-regulation of rOctI (l65.4±26.4%). Metformin alone did 
not up-regulate rOcti expression, compared to grapefruit juice or PCN. Maeda et aI, 
[263] previously presented evidence confirming PCN up-regulation, as well as 
dexamethasone [264] down-regulation of the expression of rOctI. 
The present study, therefore, shows for the first time, that despite the well known 
metabolic effects of grapefruit juice on intestinal metabolism, leading to drug 
interactions, the liver is another organ where grapefruit juice equally exerts its effects. 
Although the mechanism by which grapefruit juice up-regulated rOcti expression could 
not be established in this study, it is possible that grapefruit juice or its components, just 
like PCN, are ligands of PXR which gets activated upon exposure, and then binds to the 
relevant promoter regions, to initiate the transcription of rOctI mRNA, as well as other 
post-transcription regulator proteins, such as PKA, PKC, etc, (Figure 33). Grapefruit 
juice-mediated reversal of dexamethasone-suppressed expression of OCTI may be as a 
result of glucocorticoid receptor antagonism, which, therefore, allowed for enhanced 
expression of PXR. Glucocorticoid receptor has previously been suggested to repress 
PXR expression, leading to reduced OCTI expression [264]. Alternatively, grapefruit 
juice could be exerting a direct antagonistic effect on glucocorticoid receptor, leading to 
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increased expression of OCT1 expression (Figure 33). It may also be possible that 
regulation of OCTI activity occurs at post-transcriptional levels, whereby grapefruit juice 
either up-regulates translation of the rOctl protein, thus increasing the protein content, or 
increasing the activity of the protein. A functional in vitro study involving 
physiologically-known substrates of OCTI, such as l-methyl;-4-phenylpyridinium 
(MPP) or tetrapentylammonium (TEA), using cultured hepatocytes, could have shed 
more light on this, but such an approach was technically beyond the scope of this study. 
PXR activation by grapefruit juice or its constituent chemicals, may also suppress the 
transcription of genes coding for gluconeogenic/glycogenolytic enzymes, leading to 
increased hepatic glucose uptake, and reduced gluconeogenesis (Figure 33). This may 
explain the apparent hypoglycaemic effect of grapefruit juice. Metformin is not 
metabolised by liver enzymes, and is eliminated in the kidneys unchanged [323, 324, 
343], a process mediated by both OCTI and OCT2. The data presented here clearly 
demonstrate that metformin does accumulate in the liver tissue, contrary to earlier 
suggestions [367]. If that is the case, then what happens if hepatocytes are exposed to 
increased concentrations of metformin? OCTI is mainly found on the sinusoidal 
membrane of the hepatocytes [225, 234], and is known to effect bi-directional transport 
of substrates [249, 250]. It may be possible that OCTI-mediated transport of metformin 
across hepatocyte membrane is concentration gradient-dependent, such that at high 
plasma concentrations, metformin is largely transported into the cells, and vice versa. 
Increased accumulation of metformin in hepatocytes then leads to oxidative stress, due to 
diminished mitochondrial oxidative phosphorylation. This, therefore, causes conversion 
of pyruvate to lactate in the cytosol, which leads to lactic acidosis. Metformin has been 
shown in vitro to reduce oxygen consumption in cultured hepatocytes by inhibition of 
mitochondrial respiratory complex I [318, 319]. Grapefruit juice, in this case, may be 
guilty by association, since it facilitates metformin uptake of metformin by hepatocytes. 
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However, grapefruit juice associated increase in lactate levels in the presence of 
metformin is a clear case for concern. It appears that grapefruit juice can exacerbate lactic 
acidosis in the presence of metformin by facilitating its accumulation in hepatocytes. 
Subject to confirmation of these findings in humans, the present results suggest that 
despite its beneficial effect in the control of glycaemic index, grapefruit juice should be 
contra-indicated in diabetic patients who are on concurrent medication with metformin. 
5.2 CONCLUSIONS AND RECOMMENDATIONS FOR FUTURE STUDIES 
Grapefruit juice has metformin-like effects on hepatic metabolism of glucose: it improves 
glucose tolerance, does not influence plasma insulin, and is hypoglycaemic. Grapefruit 
juice ameliorates PCN-induced hyperglycemia, upregulates hepatic glucokinase activity, 
but down-regulates glucose-6-phosphatase (G6Pase) and phosphoenolpyruvate 
carboxykinase (PEPCK) activities, respectively, by up-regulating hepatic glucose sensor, 
adenosine monophophosphate protein kinase (AMPK). Grapefruit juice also up-regulates 
hepatic expression of rOctI , which, therefore, facilitates metformin accumulation in 
hepatocytes, leading to lactic acidosis. This suggests that although grapefruit juice 
improves glucose tolerance, and may be beneficial in diabetic patients with metabolic 
syndrome, caution should be exercised in patients who are on concurrent medication with 
metformin. Further studies in human subjects are suggested. 
Recommendations for future studies: 
i) determination of chemical ingredients of grapefruit juice responsible for 
glucose plasma glucose-lowering effect, through modulation of the activities 
of key hepatic glycolytic, gluconeogenic and glycogenolytic enzymes; 
ii) elucidation of the effects of grapefruit up-regulation of adenosine 
monophosphate protein kinase (AMPK) at molecular level since this enzyme 
has become a putative pharmacological target in the treatment of metabolic 
disorders; 
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iii) determination of the mechanism of grapefruit juice up-regulation of rOCtI at 
molecular level, using natural substrates and/or inhibitors of rOct 1 ; 
iv) clinical trials to determine the extent of grapefruit juice-induced effects on 















Enzymatic hydrolysis of naringin. Naringinase is an enzymatic complex with u-
rhamnosidase activity (hydrolyses naringin to prunin and rhamnose) and ~-glucosidase 
activity which in tum, hydrolyses prunin to naringenine and glucose, respectively. Rha-










PXR-mediated regulation of cellular expression of drug-metabolising enzymes, 
transporter proteins and other cellular proteins. Xenobiotics or endobiotic ligands bind 
intracellular PXR which gets activated and forms heterodimer with RXR. The complex 
then diffuses into the nucleus and binds relevant promoter regions of the target genes to 
initiate transcription of the mRNAs, which in tum, get translated to the relevant proteins. 
Transporter proteins are membrane bound, while the enzymes remain in the cytosol. P-gp 
extrudes its substrates from the cytoplasm, while OCT and OATPs may affect bi-
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Common bile duct 
Figure 4. 
Transproters involved in hepatic drug disposition. Drugs, bile salts and metabolites are 
taken up in the hepatocytes by SLC proteins, such as OCTl , OA TP and NTPC. Once 
inside the cell, they may undergo oxidative metabolism by CYP450 enzyme, followed by 
phase II hepatic metabolism to render them less hydrophobic. Products of phase II 
reactions may be extruded from the cell by efflux pumps, such as MRPI /MRP3 into 
systemic circulation, or P-glycoproteins (P-gp) and MRP2 into the bile canaliculi. 
Alternatively, some substrates of SLC proteins may be taken out of the cell via efflux 
pumps without metabolism. The efflux pumps help to maintain concentration gradients, 
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Schematic illustration of the structure of P-gp. The protein consists of 12 hydrophobic 
transmembrabe segments, split into 2 distinct transmembrane domains, TMD1 and 
TMD2, on the N- and C-terminus of the peptide, respectively. Each domain has a 
nucleotide binding domain, NBD1 and NBD2, respectively, on the cytoplasmic side of 
the membrane. Each NBD has the characteristic signature motif and Walker A and B, 
respectively, crucial to the hydrolysis of ATP and conformational changes of the proteins 









Proposed mechanism of action of P-gp. The classical pump, such as Na+K+-ATPase, 
transports substrates across hydrophobic membranes through hydrophilic channel of the 
transmembrane region of the protein. But the "vaccum cleaner" model of P-gp proposes 
that the drugs first partition into the lipid bilayer, and then interact with P-gp within the 
membrane, before being extruded into the aqueous phase of the extracellular side. In the 
'flippase' model, drugs partition into the membrane, interact with the drug binding pocket 
in P-gp within the cytoplasmic leaflet, and are then translocated to the outer membrane 
leaflet. Reproduced with permission from [149]. 
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Schematic representation of the proposed structure of rat Oatp 1. There are 12 
transmembrane (TMD) and 6 extracellular domains (EXD). Conserved amino acid 
residues are colour coded red, yellow (charged) and cystein (red asterisks). Potential N-
glycosylation sites are flagged with stars, while the region containing the OATP 
superfamily signature is demarcated with dotted lines at the border of EXD3 and TMD6. 
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Extracellular space 




A proposed secondary stucture of OCTl. The 12 transmembrane domains (TMD) are 
flanked by intracellular N- and C-terminus. TMDs 1 and 2 are connected by a large 
extracellular loop, which is believed to contain 3 N-linked glycosylation sites (flagged 
with red stars), while TMDs 6 and 7 are interconnected by a large intracellular loop 
containing potential phosphorylation sites (marked with red crossed circles). TMD4 and 
TMDI0 contain 3 amino acid residues each (marked with blue and red circles, 
respectively to indicate that they are conserved), while TMDII has 1 (marked with 
yellow circle). These amino acids surround a large cleft believed to be the substrate 





Schematic illustration of the transcriptional and post-transcriptional regulation of OCTI. 
In response to endogenous or exogenous agonists, HNF-4a. binds DR-2 in the promoter 
region, and activates transcription of OCTI. Other ligands may alternatively activate 
PXR which dimerizes with RXRa., and then binds DNA to initiate transcription of OCTI. 
Such ligands may concurrently trigger transcription of regulatory proteins, such as PKA, 
PKC, and calmodulin (CaM). In post-transcriptional regulation, these regulatory proteins 
may phosphorylate membrane-bound OCT! to either deactivate or activate it. Forskolin 
may activate PKA, which phosphoryaltes OCT!, and hence activating it, while 
antagonism of CaM by calmidazolium may increase substrate affinity of hOCT!. PKC 
phosphorylation of OCT! is still not well understood. Some xenobiotics may directly 










Animal weights at the beginning of the experiments (baseline), and at the end of the two-
week treatment period (end-point), for control and grapefruit juice-treated (GFJ) test rats, 
respecti vel y. 
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Figure 11 . 
A representative chromatogram of the grapefruit juice extract. The polar flavonoids 
eluted earlier (retention times <7.5), while the furanocoumarins eluted at retention times 
>7.5 minutes. 
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Mass spectrometry analysis of HPLC chromatograms of the grapefruit juice extract. 
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Figure 13. 
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Dose-response effects of grapefruit juice on plasma glucose levels of grapefruit-treated 





Fasting blood glucose levels in grapefruit juice-treated (GFJ) 'test' rats compared to 
control animals. Blood sugar was tested in rats fasted overnight for 12 hours. 
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AUC calculated from random blood glucose sampling (at 30-minute intervals) of non-
fasted but food restricted rats for a period of 90 mins. Some of the rats were previously 
(24 hrs before) treated with subcutaneous injection of PCN or polyethylene glycol {17 
mg/kg body weight (15 mglml in propylene glycol)}. PCN- and polyethylene glycol-
treated rats were previously treated with oral OFJ for 14 days, while non-OFJ-treated rats 
were either given oral metformin (with PCN) or distilled water (controls), respectively. 
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(A) 
i P =0.042 P = 0 .0017 
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Figure 16. 
Fasting blood glucose was measured in all treatment groups (A), followed by either oral 
or intraperitoneal administration of 3.0 g/kg body weight of glucose in distilled water or 
normal saline, respectively. Blood sugar levels were then monitored at 30-minute 
intervals for 90 minutes, and GTT curves constructed (B). The AUC were then calculated 
from blood glucose-time curves in control and grapefruit juice-treated test rats, 
respectively (C). The baseline values represent calculations from the animals that were 
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Figure 17. 
OTT response (A) when rats were challenged with intraperitoneal injection (i.p.) of 3.0 
glkg body weight of glucose, after treatment with either 3.0 ml/kg body weight of 
grapefruit juice, 250 mglkg body weight of metformin or both, respectively. The area-










Fasting plasma insulin levels in rats before intraperioneal injection of 3.0 glkg body 












Glycogen content of liver tissue after treatment with indicated mediators of glucose 
homeostasis. (* p<O.05). 
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Figure 20. 
Michaelis-Menten kinetics of glucokinase activity in the rat liver samples previously 
treated with different agonists in vivo. Enzyme activity was plotted against substrate 
concentrations. 
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Figure 21. 
Linear regression analysis of Eadie-Hofstee plots used to calculate Krn and Vrnax of 
glucokinase. The V-intercepts correspond to Vrnax, while the X-intercepts correspond to 
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Figure 22. 
Michaelis-Menten kinetics of glucose-6-phosphatase activity in the rat liver samples 
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Figure 23. 
Linear regression analysis of Eadie-Hofstee plots used to calculate Km and V max of 
glucose-6-phosphatse. The Y -intercepts correspond to V max, while the X-intercepts 
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Michaelis-Menten kinetics of PEPCK activity in the rat liver samples previously treated 
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PCN • rv1etformin 
Linear regression analysis of Eadie-Hofstee plots used to calculate Km and V max of 
PEPCK. The V-intercepts correspond to V max while the X-intercepts correspond to V/Km" 
values of different treatment groups respectively. Km =1/slope. 
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Figure 26, 
Michaelis-Menten kinetics of AMPK activity in the rat liver samples previously treated 
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Figure 27. 
Linear regression of Eadie-Hofstee plots used to calculate Km and V max of AMPK. The 
V-intercepts correspond to V max, while X-intercepts correspond to V/Km values of 
different treatment groups, respectively. Km =l/slope. 
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Blood lactate levels in rats that were treated with 250 mglkg body weight of metformin, 
3.0 ml/kg body weight of grapefruit juice (OFJ), or combination of both, respectively. 
Blood samples were collected 1.5 hours after the rats were challenged with 
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Figure 29. 
Linear regression analysis of metformin concentrations in liver tissue and plasma lactic 
acid levels in grapefruit-treated 'test" and 'control' rats, respectively, 1.5 hr after an oral 
dose of 250 mglkg body weight of metformin. 
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Figure 30. 
Ponceau S staining of membrane protein-rich microsomal fraction of the liver 
homogenate on PVD membrane after SDS-P AGE. 50 ~g protein from the membrane 
fractions were diluted 1:4 with sample loading buffer, and loaded into each well. 
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Immunoreactive bands after exposure to autoradiography showing the expression of 
rOctl in the rat liver after treatment with different agonists. Protein content of rOctI was 
normalised by stripping the membrane with the strip buffer and re-probing with rat anti-
rabbit Na/K-ATPase antibody as a basolateral membrane marker, in order to correct for 





Densitometry scans of rOctI expression in the rat liver. Steady-state protein level was 
expressed as a percentage of the control. 
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Figure 33 
Proposed grapefruit juice-mediated regulation of hepatic glucose metabolism and OCTI 
protein expression. Grapefruit juice or its constituent chemicals, may activate the 
expression of PXR, which in tum up-regulates the expression of rOctI, or alternatively, 
deactivates glucocorticoid receptor, which may allow for the expression of rOctI. In 
response to grapefruit juice induction, PXR may also up-regulate the expression of 
protein kinases (PKA, PKC), which may modulate the activity of rOctI either through 
direct phosphorylation, or modulation of translation of its mRNA. In response to 
grapefruit juice activation, PXR may also up-regulate AMPK (which is activated by 
metformin) to suppress the expression of gluconeogeniclglycogenolytic enzymes 
(G6Pase and PEPCK). AMPK may also activate Glut2 transporter protein to facilitate 
cellular uptake of glucose. Metformin may be transported into, and outside the cell, by 
OCTI depending on the relative concentration across the cell membrane. 
105 
6.2 TABLES 
Compounds Bioactive constituents Pharmacological Effects Potential Clinical Applications 
Flavonoids Naringinl Naringenin Antioxidant Cancer /diabetes 
(flavanones) Antineoplastic Cancer 
Anti-microbial Infection 
Antithrombotic ... Cardiovascular/ degenerative disorders, 
Vasodilator Diabetes, 
Antiinflammatory > Cancer, 
Antiatherosclerotic Degenerative disorders, 
Hypoglycemic Cancer 
Hesperidin Antineoplastic Antihistamine 
Antiinflammatory 
Limonoid Limonin Antineoplastic Cancer 
Nomilin 
Abacunone 
Furanocoumarins Bergamottin Antioxidant, Cancer 






Ascorbic acid Antioxidant Cancer/Diabetes 
Folic acid 
Potassium 
Glucaric acid Glucaric acid Antineoplastic, Diabetes 
Antihypercholesterolemia 
Highly soluble Pectin 
fibre 
Table 1. 




1, 15, 22, 26, 
27, 29, 31 
22, 30, 32 
1, 12, 20, 22, 




23, 33, 34 
1, 12 
Anticancer Beta blockers Calcium Other HIV protease Corticosteroids 
Agents channel cardiovascular inhibitors 
blockers drugs 
Docetaxel* Bunitrol Diltiazem* Digitoxin Amprevanir* Dexomethasone* 
Etoposide* Carvedilol* Milbefradil * Digoxin Indinavir* Methylprednisolone* 
Paclitaxel* Celiprolol Verapamil* Quinidine* Nelfinavir* 
Vinblastin* Talinolol Saquinavir* 
Teniposide* Ritonavir* 
Vincristine* 
Immuno- Antiemetics Statins Antihistamines Antibiotics Others 
Suppressants 
Cyclosporine* Ondansetron * Atovastatin * Fexofenadine Erythrom ycin * Amytriptyline* 
Sirolimus* Lovastatin * Terfenadine* Levofloxacin Itraconazole* 





Selected substrates of P-gp. The substrates marked with (*) are also substrates of 
CYP3A4 [172, 173, 174]. 
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Treatment 




group (ml/kg body juice (ml/kg body (mg/kg body body weigh) 
weight) weight) weight) 
Al - 0.0 - 3.0 
A2 - 1.0 - 3.0 
A3 - 2.0 - 3.0 
A4 - 3.0 - 3.0 (DEX) 
BI - 3.0 - 3.0 i.p 
B2 3.0 - - 3.0 (peN) 
B3 - 3.0 - 3.0 (peN) 
B4 3.0 - - 3.0 i.p 
CI 3.0 - - 3.0 (DEX) 
C2 3.0 - 250 3.0 (peN) 
C3 - 3.0 - 3.0 
C4 - 3.0 250 3.0 
Table 3. 
Animal treatment schedule as explained in the experimental procedure. i.p= 
intraperitoneal injection. PCN = pregnenolone-16alpha-carbonitrile (17 mg/kg body 















Ingredients Loading Loading Running Running Transfer Transfer TBS T 
Buffer Buffer Buffer Buffer Buffer Buffer 
Quantity Conc. Segarating Stacking Quantity Conc. Quantity 
W (0.375 W (4%), pH 8.3 pH 7.4 
M Tris pH (0.125 M 
8.8) pH 6.8) 
0.5 M Tris HCl 1.0 62.5 M 
Glycerol 1.6 20% 
10% SDS 1.6 20% 0.5 ml 100 ~l 
B-mercaptoethanol 0.4 5% 
0.5% Bromophenol blue 0.4 5% 
(w/v) 
30% Bis-acryl amide 16.65 ml 1.3m1 
1.5 M Tris HCl pH 8.8 12.5 ml -
0.5 M Tris HCl pH 6.8 - 2.5 
10% ammonium persulphate 250 ~l 50 ~l 
TEMED 25 ~l 50 ~l 
Trizma base 60.06 g 25mM 3.0 g 
Glycine 28.8 g 192mM 
Methanol 400ml 20% (v/v) 
Tween 20 900 ~l 
KCl 0.2 g 
NaCI 8.0 g 
Distilled water 3.0ml - 20.1 ml 6.1 ml 1600 ml 900ml 
Table 4. 
Buffers used in SDS-PAGE analysis of OCT! proteins in the liver tissue. The quantities 
added and effective concentrations are as indicated. 
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Flavonoids Unidentified 234.9 
Unidentified 272.8 
7 -geranyloxycoumarin 298.9 
Unidentified 335.1 
6', T-dihydroxybermottin 337.1 





Prominent peaks of grapefruit juice extracts separated by HPLC chromatography and 
analysed by mass spectrometry. Unidentified peaks could represent ionisation fragments 
of the constituent chemicals or dimers of the same (19). 
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o ml GFJ 1.0 ml GFJ 2.0 ml GFJ 3.0 ml GFJ 
Ave 49 1. l±28 442.8±39 416.l±35 375.3±41 
GI - 0.902 0.847 0.764 
% - 90.2 84.7 76.4 
p-value - <0.05 <0.05 <0.05 
Table 6. 
GI determined by Aue calculated from blood glucose-response to intraperitoneal 
injection of 3.0 glkg body weight of glucose (in normal saline) following treatment with 







Km (11 M) 
rl 
Vmaxl Km 
Control Dexamethasone Dexamethasone GFJ Metformin PCN Metformin 
+GFJ +PCN 
13.56±0.72· Cl> 18.66±00476· (:) 16.83±0.36· (:) 26.65±1.11 13.72±0.87 11.51±0.83 20.04±Oo406(j.J 
308 344 269 144 351 422 369 
0.5914 0.846 0.9107 0.8535 004569 0.3342 0.8835 
44 54.2 62.6 184 39.1 27.3 54.2 
Table 7. 
V max, Km and linear regression analysis of glucokinase activity determined by Eadie-
Hofstee plots. Statistically significant differences are marked by relevant symbols: 
p<O.05; in, * = GFJ with/without dexamethasone vs controls; <I> = metformin or 









Control Dexamethasone Dexamethasone GFJ Metformin PCN 
+GFJ +PCN 
13.4±0.45· CJ>~ 23.l9±0.58"" 19.26±0.41* t? 14.02±0.54 13.4±0.80
0 23.84±1.l O(J)o 
2.06# 1.705# 1.738<1> 2.292<1> 2.26 1.299" 
0.8412 0.9219 0.9400 0.7800 0.6050 0.8219 
6.5 13.6 11.08 6.11 5.9 18.35 
Table 8. 
V max, Km and linear regression analysis of G6Pase activity determined by Eadie-Hofstee 
plots. Statistically significant differences are marked by relevant symbols: p<O.05; in, * 
= dexamethasone with GFJ vs controls; <1> = peN vs controls; 0 = dexamethasone 
with/without GFJ vs controls; a = peN vs peN with metformin; # = Dexamethasone or 














Control Dexamethasone Dexamethasone GFJ Metformin PCN 
+GFJ +PCN 
13.73±0.399*# 26.78±1.17*o 10. n±0.363u 12044±Oo413 14.32±0.749'" 27.77±0.815" '" 
1.379*# 0.783* 2.784 1.552 1.398 0.7151" 
0.8141 0.9162 0.782 0.8817 0.7716 0.9506 
9.9 34.2 3.82 8.0 10.2 38.7 
Table 9. 
V max, Km and linear regression analysis of PEPCK activity determined by Eadie-Hofstee. 
Statistically significant differences are marked by relevant symbols: p<O.05; in, * = 
dexamethasone vs controls; # = peN vs controls; a = dexamethasone vs dexamethasone with 














Control Dexamethasone Dexamethasone GFJ Metformin PCN 
+GFJ +PCN 
7.44±0.4115 '" 89.94±4.757 <i> 84.71±3.949 <i> 96.44±2.478 <i> 93.74±6.55 <J) 89.75±10.08 <J) 
0.146* 0.01948* 0.03217* 0.02987* 0.0217* 0.1770 
0.5479# 0.9017# 0.8898# 0.9663# 0.8283# 0.6782 
51 4619 270.7 3228 4319 507 
Table 10. 
V max, Km and linear regression analysis of AMPK activity determined by Eadie-Hofstee. 
Statistically significant differences are marked by relevant symbols: p<0.05; in, <I> = 
controls vs all treatment groups; * = controls vs all treatment groups except PCN; # = 







Metformin Metformin Metformin 
Plasma (Ilg/ml) Liver (Ilglg) Plasma: liver ratio (%) 
Controls 9S±8.1 280±IS 33.9±S.4 
PCN 107±23 402±S8* 26.6±4.0* 
Grapefruit Juice 108±20 397±66* 27.2±3.S* 
p-value >O.OS <O.OS <O.OS 
Table II. 
Metformin levels in plasma and liver tissue I.S hrs after oral treatment with 2S0 mglkg 
body weight of metformin in control (metformin only), grapefruit juice- and PCN-treated 
animals, respectively. Plasma and liver metformin levels were analysed by HPLC as 
explained in the methods. (*) = significant difference compared to controls. 
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